[go: up one dir, main page]

WO2024173352A2 - Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a - Google Patents

Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a Download PDF

Info

Publication number
WO2024173352A2
WO2024173352A2 PCT/US2024/015542 US2024015542W WO2024173352A2 WO 2024173352 A2 WO2024173352 A2 WO 2024173352A2 US 2024015542 W US2024015542 W US 2024015542W WO 2024173352 A2 WO2024173352 A2 WO 2024173352A2
Authority
WO
WIPO (PCT)
Prior art keywords
fold greater
dose
post
cells
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/015542
Other languages
English (en)
Other versions
WO2024173352A3 (fr
Inventor
Arundathy PANDITE
Fatima RANGWALA
Thomas LAMPKIN
Taylor Schreiber
George FROMM
Suresh DE SILVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of WO2024173352A2 publication Critical patent/WO2024173352A2/fr
Publication of WO2024173352A3 publication Critical patent/WO2024173352A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Definitions

  • compositions and methods including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer comprising doses, dosing regimens that including biphasic dosing or dosing regimens comprising three cycles.
  • the instant application contains a sequence listing, which has been submitted in XML format via EFS-Web.
  • Rational dose selection and optimization of dosing regimens are of clinical importance and are prerequisites for enhancing patients’ medication compliance and obtaining maximum clinical benefits.
  • Developing dosing regimen typically relies on pharmacokinetic/pharmacodynamic studies performed in animal models.
  • immunotherapy does not exert direct anti-proliferative activity on cancer cells, but are instead expected to harness tumor immunity, typically murine surrogates are used for some animal studies, making the pharmacokinetic/pharmacodynamic studies not available.
  • physicians may vary the dosing regimen of immunotherapy based on the immunogenicity of a tumor, disease stage, and physical status of patients. Therefore, novel strategies to develop dosing and regimens are required.
  • the present disclosure is based, in part, on the discoveries of near maximal target engagement, margination certain immune cells from peripheral blood; and cytokine induction at a dosage of > 3 mg/kg of the SIRPo- Fc-CD40L chimeric protein.
  • the present disclosure provides compositions and methods that provide strategies for developing doses and dosing regimen of cancer immunotherapy.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the dose of the chimeric protein is administered at a dosage of at least about 0.3 mg/kg.
  • the chimeric protein is administered at the dosage of about 1 mg/kg.
  • the chimeric protein is administered at the dosage of about 3 mg/kg.
  • the chimeric protein having a general structure of: N terminus
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a background level and/or activity of CD40+ B cells has been measured in a pre-dose blood sample obtained from the subject before the administration of the first dose, wherein a post-dosing level and/or activity of CD40+ B cells has been measured after at
  • the post-dosing level and/or activity is measured less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level and/or activity of CD40+ B cells is lower compared to the background level and/or activity by at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level and/or activity of CD40+ B cells is the chimeric protein lower compared to the background level and/or activity by less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%.
  • the level and/or activity of CD40+ B cells is measured by contacting the sample with an agent that specifically binds to CD40 protein, a fragment and/or an epitope thereof and/or a B-cell marker, a fragment and/or an epitope thereof.
  • the B-cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD.
  • the agent that specifically binds to the CD40 protein, the fragment and/or the epitope thereof, and/or the B-cell marker, the fragment and/or the epitope thereof is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level and/or activity of CD40+ B cells is measured by immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level and/or activity of CD40+ B cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding a CD40 and/or a B-cell marker.
  • the B-cell marker is selected from CD 19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.
  • the level and/or activity of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicasedependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oli
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 have been measured after at least 15 minutes after administering the first dose; and
  • the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2- fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20- fold greater), and/or the post-dosing level and/or activity of CCL22 is at least about 2-fold greater than a predose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of IL-10 is equal or less than about 1- fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the second dose comprises substantially the same dosage as the first dose if: the postdosing level and/or activity of IL-12 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 6-fold greater, at least about 7-fold greater, at least about 8-fold greater, at least about 9-fold greater, at least about 10-fold greater, at least about 11 -fold greater, or at least about 12-fold greater), the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3- fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post- first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), and/or the postdosing level and/or activity of CCL22 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, or at least about 4-fold greater).
  • the second dose comprises an increased dosage compared to the first dose if the postdosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post- first dose amount, the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of IL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a predose amount or post-first dose amount, the post-dosing level and/or activity of CCL20 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, and/
  • the level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 is measured by contacting the sample with an agent that specifically binds to one or more of IL- 12 protein, CXCL-8 protein, CXCL-10 protein, IL-10 protein, CCL2 protein, CCL20 protein, and CCL22 protein, a fragment and/or an epitope thereof.
  • the agent that specifically binds to the IL-12 protein, CXCL-8 protein, CXCL-10 protein, IL-10 protein, CCL2 protein, CCL20 protein, and CCL22 protein, the fragment and/or the epitope thereof is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 is measured by immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 and/or a nucleic acid complementary thereto.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.
  • the level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonucle
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level of CD47 receptor occupancy of CD4 T cells and/or CD40 receptor occupancy of B cells in a post-dose blood sample obtained from the subject have been measured after at least 15 minutes after administering the first dose; and (ii) administering
  • the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is measured less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%.
  • the post-dosing level of CD40 occupancy of B cells is measured using the following formula:
  • Receptor engagement %CR @ Predose wherein %CR @ predose is the percentage of target receptor-expressing lymphocytes in a pre-dose blood sample obtained from the subject; %CR @ postdose is the percentage of target receptor-expressing lymphocytes in the post-dose blood sample; and %CRI @ postdose is the percentage of the chimeric proteinbound CD40 + B cells in the post-dose blood sample, wherein: the presence, absence, or level of CD40 + B cells has been determined in the pre-dose blood sample, the presence, absence, or level of CD40 + B cells has been determined in the post-dose blood sample, and the presence, absence, or level of the chimeric protein-bound CD40 + B cells has been determined in the post-dose blood sample.
  • the post-dosing level of CD47 occupancy of CD4 T cells is measured using the following formula:
  • Receptor occupancy [%ARC(subj) — %ARC(iso)]/[%ARC(spike) — %ARC(ISO)] wherein %ARC(subj) is the percentage of chimeric protein-bound target receptor-expressing CD4+ T lymphocytes blood sample obtained from the subject; %ARC(iso) is the percentage of chimeric protein-bound target receptor-expressing CD4+ T lymphocytes blood sample obtained from the subject, stained with only drug detecting antibody; and %ARC(spike) is the percentage of chimeric protein-bound target receptorexpressing CD4+T lymphocytes blood sample obtained from the subject with a saturating amount of chimeric protein added at processing wherein: the presence, absence, or level of CD40 + B cells has been determined in the pre-dose blood sample, the presence, absence, or level of CD40 + B cells has been determined in the post-dose blood sample, and the presence, absence, or level of the chimeric protein-bound CD40 + B cells has been determined in the post-dose blood sample.
  • the presence, absence, or level of CD47 + CD4 + T cells is measured by contacting the sample with an agent that specifically binds to one or more of CD47 protein, CD4 protein, and a T cell marker, or a fragment or an epitope thereof.
  • the T-cell marker is selected from CD3, CD4, CD8, CCR7, CD62L, CD45RA, CXCR3, CCR4, CCR5, FOXP3 and IL2RA (CD25).
  • the presence, absence, or level of CD40+ B cells is measured by contacting the sample with an agent that specifically binds to CD40 protein and/or a B cell marker, or a fragment or an epitope thereof.
  • the B-cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD.
  • the agent is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level and/or activity of CD40+ B cells is measured by immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the presence, absence, or level of CD47 + CD4 + T cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD47, CD4 and/or a T cell marker.
  • the T-cell marker is selected from CD3, CD4, CD8, CCR7, CD62L, CD45RA, CXCR3, CCR4, CCR5, FOXP3 and IL2RA (CD25).
  • the presence, absence, or level of CD40+ B cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and/or a B cell marker.
  • the B-cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.
  • the presence, absence, or level of CD47 + CD4 + T cells and/or presence, absence, or level of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonucleotide arrays (Gene Chip
  • the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg. In embodiments, the first dose of the chimeric protein is in the range of from about 0.3 mg/kg to 10 mg/kg. In embodiments, the first dose is about 0.3 mg/kg, or about 1 mg/kg, or about 2 mg/kg, or about 3 mg/kg, or about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the first dose is in the range of about 0.3 mg/kg to about 2 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 4 mg/kg, or about 3 mg/kg to about 6 mg/kg, or about 5 mg/kg to about 10 mg/kg.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a background level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells has been measured in a pre-dose blood sample obtained from the subject before the administration of the first dose, wherein a post-dosing level
  • the post-dosing level and/or activity is measured more than about 12, or more than about 16, or more than about 18, or more than about 24, or more than about 28, or more than about 32, or more than about 40, or more than about 48 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is lower compared to the background level and/or activity by at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is the chimeric protein not lower compared to the background level and/or activity by less than about 55%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by contacting the sample with an agent that specifically binds to CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker.
  • the B-cell marker is selected from CD 19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD
  • the marker specific to CD40 expressing monocytes is selected from CD163, CD192, CD14, CD11 b, CCR2, CD16, CD141 , CD11c, HLA-DR, and CCR7
  • the CD4 T cell marker is selected from CD4, CD25, CD127, FoxP3, CCR4, Cith2, CCR6, CXCR5, CD39, CD45RA, CTLA-4, CD127, IL-2R, IL-4R, IL-9R, IL-15R, IL-21 R, and CD25.
  • the agent that specifically binds to CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker.
  • the B-cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD
  • the marker specific to CD40 expressing monocytes is selected from CD163, CD192, CD14, CD11 b, CCR2, CD16, CD141, CD11c, HLA-DR, and CCR7
  • the CD4 T cell marker is selected from CD4, CD25, CD127, FoxP3, CCR4, Cith2, CCR6, CXCR5, CD39, CD45RA, CTLA- 4, CD127, IL-2R, IL-4R, IL-9R, IL-15R, IL-21 R, and CD25.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid probe
  • the level and/or activity of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonu
  • the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a background amount and/or activity of M1 macrophages, M2 macrophages and/or granzyme B producing-T cells has been measured in a pre-dose biological sample obtained from the subject before the administration of the first dose, and wherein a postdose amount and/or activity of M1 macrophages
  • the post-dosing level and/or activity is measured more than about 12, or more than about 16, or more than about 18, or more than about 24, or more than about 28, or more than about 32, or more than about 40, or more than about 48 hours, or more post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post dosing amount and/or activity of the granzyme B producing-T cells is greater than the background amount and/or activity of the granzyme B producing-T cells by at least about 1 .25*, or at least about 1 .5*, or at least about 2x, or at least about 5*, or at least about 10x, or more.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing ratio of amount and/or activity of the M1 macrophages to M2 macrophages is greater than the pre-dose ratio of amount and/or activity of the M1 macrophages to M2 macrophages by at least about 1 .25*, or at least about 1.5*, or at least about 2x, or at least about 5x, or at least about 10x, or more.
  • the second dose comprises an increased dosage compared to the first dose if the post dosing amount and/or activity of the granzyme B producing-T cells is not greater than the background amount and/or activity of the granzyme B producing-T cells by at least about 1.2x, or at least about 1 x. In embodiments, the second dose comprises an increased dosage compared to the first dose if the post-dosing ratio of amount and/or activity of the M1 macrophages to M2 macrophages is not greater than the pre-dose ratio of amount and/or activity of the M1 macrophages to M2 macrophages by at least about 1 .2x, or at least about 1 x.
  • the biological sample is selected from blood, plasma, serum, blood cells, lacrimal fluid, tears, bone marrow, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage, aspirate, scraping, bone marrow specimen, a biopsy specimen and a surgical specimen.
  • the biological sample is a biopsy sample or a surgical specimen, optionally wherein the biological sample is a tumor biopsy sample or a tumor surgical specimen.
  • the tumor biopsy sample or the tumor surgical specimen derived from a tumor selected ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the level of the cell is measured by RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level of the cell is measured by contacting the sample with an agent that specifically binds to a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells.
  • the marker specific to M1 macrophages is selected from CD80, CD86, CD64, CD16, CD32, and nitric oxide synthase (iNOS), the marker specific to M2 macrophages is selected from CD163, CD206, CD68, arginase 1 (Arg1) and DECTIN-1.
  • the marker specific to granzyme B producing-T cells is selected from granzyme B (GrzB), CD69 and integrin aE (CD103).
  • the agent that specifically binds to the a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells is an antibody or fragment thereof
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level of the cell is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells.
  • the marker specific to M1 macrophages is selected from CD80, CD86, CD64, CD16, CD32, and nitric oxide synthase (iNOS), the marker specific to M2 macrophages is selected from CD163, CD206, CD68, arginase 1 (Arg1) and DECTIN-1.
  • the marker specific to granzyme B producing-T cells is selected from granzyme B (GrzB), CD69 and integrin aE (CD103).
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.
  • the level and/or activity of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonucleotide arrays (Gene Chips).
  • PCR polymerase chain reaction
  • RT-PCR reverse transcriptase
  • the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 6 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 10 mg/kg.
  • the first domain is capable of binding a CD172a (SIRPa) ligand.
  • the first domain comprises substantially all of the extracellular domain of CD172a (SIRPa).
  • the first domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57.
  • the second domain is capable of binding a CD40 receptor.
  • the second domain comprises substantially all of the extracellular domain of CD40L.
  • the second domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 58.
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from lgG4. In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human lgG4. In embodiments, the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the first domain comprises the amino acid sequence of SEQ ID NO: 57
  • the second domain comprises the amino acid sequence of SEQ ID NO: 58
  • the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7.
  • the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 and SEQ ID NO: 7.
  • the chimeric protein comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the method of any of the aspects disclosed herein further comprises administration of a second dose of the chimeric protein.
  • the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after the administration of the first dose.
  • the second dose of the chimeric protein is in the range of from about 0.3 mg/kg to 10 mg/kg.
  • the second dose is about 0.3 mg/kg, or about 1 mg/kg, or about 2 mg/kg, or about 3 mg/kg, or about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg. In embodiments, the second dose is in the range of about 0.3 mg/kg to about 2 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 4 mg/kg, or about 3 mg/kg to about 6 mg/kg, or about 5 mg/kg to about 10 mg/kg.
  • the human subject suffers from or is suspected to suffer from an advanced solid tumor or a lymphoma.
  • the human subject suffers from or is suspected to suffer from a cancer is selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the human subject has failed one or more platinum-based therapies.
  • the human subject is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • the human subject has failed one or more platinum-based therapies.
  • the human subject is ineligible for a further platinum therapy.
  • the human subject is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • FIG. 1A to FIG. 1 F summarize the study design of phase 1 clinical trial of the SIRPa-Fc-CD40L chimeric protein (SL-172154), study subject and tumor characteristics, and adverse events (AEs).
  • FIG. 1A shows a diagrammatic representation of the SIRPa-Fc-CD40L chimeric protein (SL-172154).
  • SL-172154 (SIRPa-Fc- CD40L) is a hexameric, bi-functional fusion protein consisting of SIRPa (binding affinity to CD47 is 0.628 nM) linked to CD40L (binding affinity to CD40 is 4.74 nM) through an Fc linker protein.
  • FIG. 1 B shows a diagrammatic representation of the phase 1 dose escalation study.
  • FIG. 1C shows the details of the study population.
  • FIG. 1D shows the details of the tumor characteristics.
  • FIG. 1 E tabulates all causality AEs observed in >3 subjects.
  • FIG. 1F shows the drug-related AEs (any grade) observed in >10% subjects.
  • FIG. 2A to FIG. 2E summarize the pharmacokinetics of the SIRPa-Fc-CD40L chimeric protein (SL-172154).
  • FIG. 2A shows a Cycle 1 Day 1 concentration profile.
  • FIG. 2B shows Cmax and AUC at Cycle 1 Day 1.
  • SL- 172154 Cmax and AUC increased with dose with greater than proportional exposure noted at 3 and 10 mg/kg.
  • FIG. 2C shows dose-normalized PK parameters at Cycle 1 Day 1 (C1 D1) (left panels), Cycle 1 Day 15 (C1 D1) (middle panels), and Cycle 2 Day 1 (C1 D1) (right panels). Cmax/D (top panels) and AUCiast/D (bottom panels) are shown.
  • FIG. 2D shows dose-normalized Cmax, which is the maximum observed concentration.
  • FIG. 2E shows dose-normalized AUCiast, which is the area under the curve, time 0 to last concentration.
  • FIG. 3A and FIG. 3B demonstrate that SL-172154 binds to B cells and stimulates B cell margination.
  • FIG. 3A shows CD40 engagement of CD40+ B cells across doses of SL-127154.
  • FIG. 3B shows dose-dependent egress of CD40+ B cells with maximal egress noted at 1 mg/kg and 3 mg/kg.
  • FIG. 4A and FIG. 4B demonstrate the binding of SL-172154 to CD47 + cells.
  • FIG. 4A shows percentage receptor occupancy of CD47 on CD4 T cell with maximal occupancy noted between 1 mg/Kg and 3 mg/Kg. Without wishing to be bound by theory, the reduction of receptor occupancy seen at 10 mg/Kg may be due to CD4 T cell egress.
  • FIG. 4B shows the CD47 receptor saturation on CD4 T cells.
  • FIG. 5 shows dose-dependent egress of CD4 T cells. Without wishing to be bound by theory, the reduction of receptor occupancy seen at 10 mg/Kg may be due to CD4 T cell egress.
  • FIG. 6A to FIG. 6K show dose-dependent & persistent cytokine responses: IL-12, CXCL-10, CCL-22, CXCL- 8 and IL-10.
  • FIG. 6A shows a dose-dependent induction of IL-12.
  • FIG. 6B shows the induction of IL-12 and return to normal levels before the next dose.
  • FIG. 6C and FIG. 6D show a dose-dependent induction of CXCL-8.
  • FIG. 6E and FIG. 6F show a dose-dependent induction of CXCL-10.
  • FIG. 6G and FIG. 6H shows a dose-dependent induction of IL-10.
  • FIG. 61 shows a dose-dependent induction of CCL2.
  • FIG. 6J shows a dose-dependent induction of n CCL20.
  • FIG. 6K shows a dose-dependent induction of CCL22.
  • FIG. 7A to FIG. 7C show that SL-172154 Stimulates dose-dependent margination of B cells (FIG. 7A), CD40 monocytes (FIG. 7B) and CD4 T cells (FIG. 7C).
  • FIG. 8A and FIG. 8B show the PK/PD model simulation in B cell margination (FIG. 8A) and IL-12 stimulation (FIG. 8B) demonstrating the pharmacodynamic activity at 3 mg/kg.
  • FIG. 9A to FIG. 9C show the changes in tumor nest induced by SL-172154.
  • FIG. 9A shows immunofluorescence images demonstrating the induction of CD68, CD206, MHC II, CD3, CD8 and granzyme B-expressing cells after dosing with SL-172154.
  • FIG. 9B and FIG. 9C show the induction of polarization of M1 macrophages (FIG. 9B) and infiltration of cytotoxic T cells (FIG. 9C) in the tumor nest
  • the present disclosure is based, in part, on the discoveries that (1) the target engagement of CD47 on CD4 T cells and CD40 on B cells approaches 100% by the 3 mg/kg dose level of the SIRPa-Fc-CD40L chimeric protein; (2) the margination CD40+ B cells from peripheral blood following the administration of the SIRPa- Fc-CD40L chimeric protein reaches maximum at the dosages > 3 mg/kg, and (3) the induction of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 following the administration of the SIRPa-Fc-CD40L chimeric protein approached a plateau at the dosages >3 mg/kg.
  • IRR infusion related reaction
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the dose of the chimeric protein is administered at a dosage of at least about 0.3 mg/kg.
  • the chimeric protein is administered at the dosage of about 1 mg/kg.
  • the chimeric protein is administered at the dosage of about 3 mg/kg.
  • the chimeric protein having a general structure of: N terminus
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 have been measured after at least 15 minutes after administering the first dose; and
  • the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2- fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20- fold greater), and/or the post-dosing level and/or activity of CCL22 is at least about 2-fold greater than a predose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of IL-10 is equal or less than about 1- fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the second dose comprises substantially the same dosage as the first dose if: the postdosing level and/or activity of IL-12 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 6-fold greater, at least about 7-fold greater, at least about 8-fold greater, at least about 9-fold greater, at least about 10-fold greater, at least about 11 -fold greater, or at least about 12-fold greater), the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3- fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post- first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), and/or the postdosing level and/or activity of CCL22 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, or at least about 4-fold greater).
  • the second dose comprises an increased dosage compared to the first dose if the postdosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post- first dose amount, the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of IL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a predose amount or post-first dose amount, the post-dosing level and/or activity of CCL20 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, and/
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level of CD47 receptor occupancy of CD4 T cells and/or CD40 receptor occupancy of B cells in a post-dose blood sample obtained from the subject have been measured after at least 15 minutes after administering the first dose; and (ii) administering
  • the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is measured less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%.
  • the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is measured using the following formula:
  • Receptor engagement %CR @ Predose wherein %CR @ predose is the percentage of target receptor-expressing lymphocytes in a pre-dose blood sample obtained from the subject; %CR @ postdose is the percentage of target receptor-expressing lymphocytes in the post-dose blood sample; and %CRI @ postdose is the percentage of the chimeric proteinbound CD47 + CD4 + T cells and/or the chimeric protein-bound CD40 + B cells in the post-dose blood sample, wherein: the presence, absence, or level of CD47 + CD4 + T cells and/or CD40 + B cells has been determined in the pre-dose blood sample, the presence, absence, or level of CD47 + CD4 + T cells and/or CD40 + B cells has been determined in the post-dose blood sample, and the presence, absence, or level of the chimeric protein-bound CD47 + CD4 + T cells and/or the chimeric protein-bound CD40 + B cells has been determined in the post-dose blood sample.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the chimeric protein is administered by infusion wherein a post-dosing infusion related reaction (IRR) monitored during and immediately after the administration a dose; and (ii) slowing the rate of infusion if an IRR is observed during the dose and/or
  • the rate of infusion is decreased to about 90%, or about 80%, or about 75%, or about 70%, or about 60%, or about 50%, or about 40%, or about 33%, or about 30%, or about 25%, or about 20%, or less of the starting infusion rate.
  • the IRR is selected from headache, nausea, chills, pruritus, urticaria, fever, rigors, diaphoresis, dizziness, flush, bronchospasms, chest, and back pain.
  • a chimeric protein of the present disclosure via binding of the extracellular domain of CD172a (SIRPa) to its receptor/ligand on a cancer cell) disrupts, blocks, reduces, inhibits, and/or sequesters the transmission of immune inhibitory signals, e.g., originating from a cancer cell that is attempting to avoid its phagocytosis and/or destruction, and via binding of CD40L to its receptor) enhances, increases, and/or stimulates the transmission of an immune stimulatory signal to an anti-cancer immune cell, it can provide an anti-tumor effect by two distinct pathways; this dual-action is more likely to provide any anti-tumor effect in a patient and/or to provide an enhanced anti-tumor effect in a patient.
  • SIRPa extracellular domain of CD172a
  • chimeric proteins can act via two distinct pathways, they can be efficacious, at least, in patients who respond poorly to treatments that target one of the two pathways. Thus, a patient who is a poor responder to treatments acting via one of the two pathways, can receive a therapeutic benefit by targeting the other pathway.
  • the chimeric proteins of the present disclosure comprise an extracellular domain of CD172a (SIRPa) and an extracellular domain of CD40L which together can simultaneously block immune inhibitory signals and stimulate immune activating signals.
  • SIRPa CD172a
  • CD40L extracellular domain of CD40L
  • aspects of the present disclosure provide a chimeric protein comprising a general structure of: N terminus -
  • (b) is a linker adjoining the first domain and the second domain, e.g., the linker comprising at least one cysteine residue capable of forming a disulfide bond and/or comprising a hinge-CH2-CH3 Fc domain, and
  • (c) is a second domain comprising an extracellular domain of CD40L; wherein the linker connects the first domain and the second domain.
  • the first domain comprises substantially all of the extracellular domain of CD172a (SIRPa). In embodiments, the first domain is capable of binding a CD172a (SIRPa) ligand. In embodiments, the first domain is capable of binding a CD172a (SIRPa) ligand (e.g., CD47) expressed on cancer cell surface. In embodiments, the first domain is capable of inhibiting the binding of a CD172a (SIRPa) ligand e.g., CD47) to the CD172a (SIRPa) protein located on myeloid and hematopoietic stem cells and neurons. In embodiments, the first domain is capable of inhibiting an immunosuppressive signal.
  • the first domain is capable of inhibiting an immunosuppressive signal. In embodiments, the first domain is capable of inhibiting a macrophage checkpoint or “do not eat me” signal.
  • the therapy with the SIRPa- Fc-CD40L chimeric protein e.g., SEQ ID NO: 59 or SEQ ID NO: 61 stimulates macrophages to phagocytize tumor cells and effectively present the tumor antigens of phagocytized tumor cells to T cells.
  • the second domain is capable of binding a CD40 receptor. In embodiments, the second domain comprises substantially all of the extracellular domain of CD40L. In embodiments, the second domain is capable of activating an immune stimulatory signal.
  • the chimeric protein is a recombinant fusion protein, e.g., a single polypeptide having the extracellular domains disclosed herein.
  • the chimeric protein is translated as a single unit in a prokaryotic cell, a eukaryotic cell, or a cell-free expression system.
  • the presentchimeric protein is producible in a mammalian host cell as a secretable and fully functional single polypeptide chain.
  • chimeric protein refers to a recombinant protein of multiple polypeptides, e.g., multiple extracellular domains disclosed herein, that are combined ⁇ via covalent or non-covalent bonding) to yield a single unit, e.g., in vitro ⁇ e.g., with one or more synthetic linkers disclosed herein).
  • the chimeric protein is chemically synthesized as one polypeptide, or each domain is chemically synthesized separately and then combined. In embodiments, a portion of the chimeric protein is translated, and a portion is chemically synthesized.
  • an extracellular domain refers to a portion of a transmembrane protein which is capable of interacting with the extracellular environment. In embodiments, an extracellular domain refers to a portion of a transmembrane protein which is sufficient for binding to a ligand or receptor and is effective in transmitting a signal to a cell. In embodiments, an extracellular domain is the entire amino acid sequence of a transmembrane protein which is normally present at the exterior of a cell or of the cell membrane.
  • an extracellular domain is that portion of an amino acid sequence of a transmembrane protein which is external of a cell or of the cell membrane and is needed for signal transduction and/or ligand binding as may be assayed using methods know in the art ⁇ e.g., in vitro ligand binding and/or cellular activation assays).
  • Transmembrane proteins typically consist of an extracellular domain, one or a series of transmembrane domains, and an intracellular domain.
  • the extracellular domain of a transmembrane protein is responsible for interacting with a soluble receptor or ligand or membrane-bound receptor or ligand ⁇ i.e., a membrane of an adjacent cell).
  • the transmembrane domain(s) is responsible for localizing the transmembrane protein to the plasma membrane.
  • the intracellular domain of a transmembrane protein is responsible for coordinating interactions with cellular signaling molecules to coordinate intracellular responses with the extracellular environment (or visa-versa).
  • Type I transmembrane proteins which have an extracellular amino terminus and an intracellular carboxy terminus
  • Type II transmembrane proteins which have an extracellular carboxy terminus and an intracellular amino terminus.
  • Type I and Type II transmembrane proteins can be either receptors or ligands.
  • Type I transmembrane proteins ⁇ e.g., CD172a (SIRPo)
  • SIRPo ligands for Type I transmembrane proteins
  • the amino terminus of the protein faces outside the cell, and therefore contains the functional domains that are responsible for interacting with other binding partners (either ligands or receptors) in the extracellular environment.
  • Type II transmembrane proteins ⁇ e.g., CD40L
  • the carboxy terminus of the protein faces outside the cell, and therefore contains the functional domains that are responsible for interacting with other binding partners (either ligands or receptors) in the extracellular environment.
  • these two types of transmembrane proteins have opposite orientations to each other relative to the cell membrane.
  • CD47 as a “do not eat me” signal in a broad range of cancers stimulated exploration of what combinations of “eat me” signals may enhance antitumor immunity in the setting of CD47 blockade.
  • SIRPa CD47-signal regulatory protein alpha
  • At least 50% of patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma treated with Hu5F9-G4, a humanized, lgG4 isotype, CD47-blocking mAb, in combination with rituximab demonstrate objective responses.
  • CD47 blockade enhances antigen presentation in immune-neglected tumors (Tseng et al., Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110:11103-11108 (2013)), yet only sporadic clinical responses have been observed using CD47/SIRPO blocking therapeutics as monotherapy or in combination with PD-1/L1 -blocking antibodies.
  • CD47/SIRPa blockade induces antitumor activity by increasing the phagocytosis of tumor cells by macrophages and enhancing the cross-presentation of tumor antigens to CD8+T cells by dendritic cells; both of these processes are potentiated by CD40 signaling.
  • SIRPa-Fc-CD40L a novel, two-sided fusion protein incorporating the extracellular domains of SIRPo and CD40L, adjoined by a central Fc domain, termed SIRPa-Fc-CD40L was generated.
  • the SIRPa-Fc-CD40L chimeric protein bound CD47 and CD40 with high affinity and activated CD40 signaling in the absence of Fc receptor cross-linking. No evidence of hemolysis, hemagglutination, or thrombocytopenia was observed in vitro or in cynomolgus macaques. Further, as shown herein, the SIRPa- Fc-CD40L chimeric protein outperformed CD47 blocking and CD40 agonist antibodies in murine CT26 tumor models and synergized with immune checkpoint blockade of PD-1 and CTLA4.
  • SIRPa-Fc-CD40L activated a type I interferon response in macrophages and potentiated the activity of ADCP-competent targeted antibodies both in vitro and in vivo.
  • Chimeric proteins of the present disclosure comprise an extracellular domain of CD172a (SIRPo) and an extracellular domain of CD40L.
  • a chimeric protein of the present disclosure comprises, at least, a first domain comprising the extracellular domain of CD172a (SIRPo), which is connected - directly or via a linker - to a second domain comprising the extracellular domain of CD40L.
  • the domains are linked in an amino-terminal to carboxy-terminal orientation, the first domain is located on the “left”’ side of the chimeric protein and is “outward facing” and the second domain is located on “right” side of the chimeric protein and is “outward facing.”
  • first and second domains are envisioned, e.g., the first domain is outward facing and the second domain is inward facing, the first domain is inward facing and the second domain is outward facing, and the first and second domains are both inward facing.
  • the chimeric protein would have an amino-terminal to carboxy-terminal configuration comprising an extracellular domain of CD40L, a linker, and an extracellular domain of CD172a (SIRPo).
  • SIRPo extracellular domain of CD172a
  • Constructs could be produced by cloning of the nucleic acids encoding the three fragments (the extracellular domain of CD172a (SIRPo), followed by a linker sequence, followed by the extracellular domain of CD40L) into a vector (plasmid, viral or other) wherein the amino terminus of the complete sequence corresponded to the ‘left’ side of the molecule containing the extracellular domain of CD172a (SIRPo) and the carboxy terminus of the complete sequence corresponded to the ‘right’ side of the molecule containing the extracellular domain of CD40L.
  • a vector plasmid, viral or other
  • a construct would comprise three nucleic acids such that the translated chimeric protein produced would have the desired configuration, e.g., a dual inward-facing chimeric protein. Accordingly, in embodiments, the present chimeric proteins are engineered as such.
  • the chimeric protein is capable of contemporaneously binding the human CD172a (SIRPa) ligand and the human CD40 receptor, wherein the CD172a (SIRPa) ligand is CD47 and the CD40L receptor is CD40.
  • the chimeric protein has a general structure of: N terminus - (a) - (b) - (c) - C terminus, in which (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L).
  • the linker comprises at least one cysteine residue capable of forming a disulfide bond.
  • Chimeric proteins of the present disclosure have a first domain which is sterically capable of binding its ligand/receptor and/or a second domain which is sterically capable of binding its ligand/receptor.
  • This flexibility and/or physical distance (which is herein referred to as “slack”) may be normally present in the extracellular domain(s), normally present in the linker, and/or normally present in the chimeric protein (as a whole).
  • the chimeric protein may be modified by including one or more additional amino acid sequences (e.g., the joining linkers described below) or synthetic linkers (e.g., a polyethylene glycol (PEG) linker) which provide additional slack needed to avoid steric hindrance.
  • additional amino acid sequences e.g., the joining linkers described below
  • synthetic linkers e.g., a polyethylene glycol (PEG) linker
  • the chimeric proteins of the present disclosure comprise variants of the extracellular domain of CD172a (SIRPa).
  • the variant may have at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71 %, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 60%,
  • the extracellular domain of CD172a (SIRPa) has the following amino acid sequence:
  • a chimeric protein comprises a variant of the extracellular domain of CD172a (SIRPa).
  • the variant may have at least about 60%, or at least about 61 %, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71 %, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81 %, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%,
  • the first domain of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 57.
  • the first domain of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 57.
  • the chimeric proteins of the present disclosure comprise variants of the extracellular domain of CD40L.
  • the variant may have at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71 %, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91
  • the extracellular domain of CD40L has the following amino acid sequence:
  • a chimeric protein comprises a variant of the extracellular domain of CD40L.
  • the variant may have at least about 60%, or at least about 61 %, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81 %, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91
  • the second domain of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 58.
  • the second domain of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 58.
  • the linker of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1 , SEO ID NO: 2, or SEO ID NO: 3. In embodiments, the linker of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
  • the linker of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO:
  • the linker of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence that is at least 95% identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is at least 95% identical to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence that is at least 97% identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is at least 97% identical to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is at least 97% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence that is at least 98% identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is at least 98% identical to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence that is at least 99% identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is at least 99% identical to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEO ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence of SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence of SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
  • a chimeric protein of the present disclosure comprises: (1) a first domain comprising the amino acid sequence identical to SEQ ID NO: 57, (b) a second domain comprises the amino acid sequence that is to SEQ ID NO: 58, and (c) a linker comprises an amino acid sequence that is that is identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
  • a CD172a (SIRPa)-Fc-CD40L chimeric protein of the present disclosure has the following amino acid sequence (the extracellular domain of CD172a (SIRPa) is shown in a boldface font, the extracellular domain of CD40L is indicated by underline, Fc domain is shown in italic:
  • the 792 amino acid sequence of the CD172a (SIRPa)-Fc-CD40L chimeric protein (SL-172154) (not including the leader sequence) is shown above.
  • the CD172a (SIRPo)-Fc-CD40L chimeric protein exists as a profile of oligomeric forms. There are 17 cysteines in the amino acid sequence with 8 likely disulfide pairs. Both N and O-linked glycosylation have been identified.
  • the chimeric protein of the present disclosure comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 potential N glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least two potential N glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least four potential N glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least six potential N glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least eight potential N glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least ten potential N glycosylation sites.
  • the chimeric protein of the present disclosure comprises at least 1 , 2, 3, 4, 5, 6, 7, or 8 potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least two potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least four potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least six potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least eight potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least two potential N glycosylation sites, and at least two potential 0 glycosylation sites.
  • the chimeric protein of the present disclosure comprises at least four potential N glycosylation sites, and at least four potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least six potential N glycosylation sites, and at least six potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least eight potential N glycosylation sites, and at least eight potential 0 glycosylation sites. In embodiments, the chimeric protein of the present disclosure comprises at least ten potential N glycosylation sites, and at least eight potential 0 glycosylation sites. In embodiments, the chimeric protein expressed in Chinese Hamster Ovary (CHO) cells is glycosylated.
  • cysteines present in the SL-172154 chimeric protein.
  • the SL-172154 chimeric protein has no disulfide bonds.
  • the SL-172154 chimeric protein has at least one, or at least two, or at least 3, or at least 4, or at least 5, or at least 6, or at least 7, or at least 8, or at least 9, or at least 10 disulfide bonds.
  • the SL-172154 chimeric protein has at least one, or at least two interchain disulfide bonds.
  • the SL-172154 chimeric protein has at least one, or at least two, or at least 3, or at least 4, or at least 5, or at least 6, or at least 7, or 8 intrachain disulfide bonds.
  • the CD172a (SIRPo)-Fc-CD40L chimeric protein of the present disclosure is encoded by the following nucleotide sequence (leader sequence is shown by a bold-underlined font):
  • the SEQ ID NO: 60 encodes for a precursor of the CD172a (SIRPa)-Fc-CD40L chimeric protein of the present disclosure having the following amino acid sequence (leader sequence is shown by an italic font):
  • the chimeric protein of SEQ ID NO: 59 (also referred to herein as SL-172154) is a recombinant fusion glycoprotein comprising the extracellular domain of human CD172a (SIRPa) (PDCD1 , CD272a), a central domain including the hinge-CH2-CH3 region from human immunoglobulin constant gamma 4 (Inhibitory receptor SHPS-1 , 1 gG4), and the extracellular domain of human CD40L (TNFSF5, TRAP, CD154).
  • SIRPa human CD172a
  • PDCD1 , CD272a a central domain including the hinge-CH2-CH3 region from human immunoglobulin constant gamma 4 (Inhibitory receptor SHPS-1 , 1 gG4)
  • TNFSF5 TRAP TRAP
  • the predicted molecular weight for the monomeric chimeric protein of SEQ ID NO: 59 is 88.1 kDa.
  • the predicted molecular weight for the glycosylated monomeric chimeric protein of SEQ ID NO: 59 is about 115 kDa.
  • chimeric proteins disclosed herein such as the CD172a (SIRPa)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), is designed to intercept one of the key immunosuppressive pathways within the tumor microenvironment (TME): the CD172a (SIRPa) - CD47 macrophage checkpoint.
  • TAE tumor microenvironment
  • Tumor cells may express CD47 on their cell surface, which can bind to CD172a (SIRPa) expressed by a macrophage to suppress phagocytosis of the tumor cells.
  • CD172a SIRPa
  • Fc-CD40L chimeric protein e.g.
  • SEQ ID NO: 59 or SEQ ID NO: 61 can bind to CD47 expressed on the surface of tumor, with the CD172a (SIRPa) domain of the CD172a (SIRPa)-Fc-CD40L chimeric proteins disclosed herein intended to provide competitive inhibition of CD47, and to replace the CD47 inhibitory signal with functionally trimerized/hexamerized CD40L, resulting in an incoming T cell experiencing co-stimulation via engagement through its CD40 receptor instead of suppression through CD172a (SIRPa) interactions.
  • SIRPa CD172a domain of the CD172a (SIRPa)-Fc-CD40L chimeric proteins disclosed herein intended to provide competitive inhibition of CD47, and to replace the CD47 inhibitory signal with functionally trimerized/hexamerized CD40L, resulting in an incoming T cell experiencing co-stimulation via engagement through its CD40 receptor instead of suppression through CD172a (SIRPa) interactions.
  • tumor infiltrating T cells will receive co-stimulation at the same time they recognize a tumor antigen via its T cell receptor (TCR).
  • TCR T cell receptor
  • the ECDs of CD172a (SIRPa) and CD40L are physically linked to one another, and localized to the TME, tumor infiltrating T cells will receive costimulation at the same time they recognize a tumor antigen via the T cell receptor. Together, these would result in replacement of an inhibitory CD47 signal with a co-stimulatory CD40L signal to enhance the antitumor activity of T cells.
  • the extracellular domain of CD172a (SIRPa) normally exists as a monomer and is not known to form higher order homomeric complexes.
  • the central Fc domain contains cysteine residues that are capable of disulfide bonding to form a dimeric structure.
  • the chimeric proteins disclosed herein including the CD172a (SIRPo)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), contains an S228P mutation in the hinge region of the Fc domain to prevent Fab arm exchange.
  • the CD40L domain is known to form homotrimeric complexes, which are stabilized through noncovalent, electrostatic interactions.
  • the chimeric proteins disclosed herein, including the CD172a (SIRPa)-Fc-CD40L chimeric protein e.g.
  • SEQ ID NO: 59 or SEQ ID NO: 61 are expressed as a continuous monomeric protein by production cell lines, the resulting monomeric proteins self-assemble into higher-order species based on these disulfide and charge-based interactions of CD40L (creating a trimer) and the combined influence of these attractive forces, resulting in a hexamer (dimer of trimers).
  • the majority (>80%) of the CD172a (SIRPo)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) comprises the hexamer and trimer forms, which have similar activity.
  • CD172a (SIRPa)-Fc-CD40L chimeric protein e.g., SEQ ID NO: 59 or SEQ ID NO: 61
  • SEQ ID NO: 59 or SEQ ID NO: 61 are comprised of hexamers and trimers, they stimulate CD40 signaling in the absence of cross-linking by Fc receptors or any other cross-linking agent.
  • the predicted tertiary structures of the CD172a (SIRPa)-Fc-CD40L chimeric protein e.g.
  • SEQ ID NO: 59 or SEQ ID NO: 61 as a monomer and in various oligomeric states, based on disulfide (Fc) and charge-based (CD40L) interactions shows visualization by electron microscopy of the CD172a (SIRPo)-Fc-CD40L chimeric protein (e.g. SEQ ID NO: 59 or SEQ ID NO: 61) hexamers (top two images) and the CD172a (SIRPa)-Fc- CD40L chimeric protein (e.g. SEQ ID NO: 59 or SEQ ID NO: 61) trimers (bottom two images).
  • the CD172a (SIRPa)-Fc-CD40L chimeric protein forms trimers/hexamers and activates CD40 without the need for cross-linking. It is noteworthy that, unlike monoclonal antibodies, Fc receptor cross-linking is not required for functional activity of the CD172a (SIRPa)- Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61).
  • a chimeric protein comprises a variant of the CD172a (SIRPa)-Fc-CD40L chimeric protein (e.g, SEQ ID NO: 59 or SEQ ID NO: 61).
  • the variant may have at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81 %, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about
  • the first domain of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61 .
  • the first domain of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the first domain is capable of binding a CD172a (SIRPa) ligand.
  • the first domain comprises substantially all of the extracellular domain of CD172a (SIRPa).
  • the second domain is capable of binding a CD40 receptor.
  • the second domain comprises substantially all of the extracellular domain of CD40L.
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from lgG4, e.g., human lgG4.
  • the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the linker comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the first domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 57.
  • the first domain of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 57.
  • the second domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 58.
  • the second domain of a chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the second domain of a chimeric protein comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 58.
  • the (a) the first domain comprises the amino acid sequence of SEQ ID NO: 57
  • the second domain comprises the amino acid sequence of SEQ ID NO: 58
  • the linker comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the chimeric protein further comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 5 and/or SEQ ID NO: 7. In embodiments, the chimeric protein further comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5 and/or SEQ ID NO: 7. In embodiments, the chimeric protein further comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 5 and/or SEQ ID NO: 7. In embodiments, the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 and/or SEQ ID NO: 7.
  • the chimeric protein comprises an amino acid sequence that is at least about 95% identical to SEQ ID NO: 59 or SEQ ID NO: 61 , e.g., at least about 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61 , at least about 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61, at least about 99.2% identical to SEQ ID NO: 59 or SEQ ID NO: 61, at least about 99.4% identical to SEQ ID NO: 59 or SEQ ID NO: 61 , at least about 99.6% identical to SEQ ID NO: 59 or SEQ ID NO: 61 , or at least about 99.8% identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the chimeric protein comprises the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the chimeric protein may comprise an amino acid sequence having one or more amino acid mutations relative to any of the protein sequences disclosed herein.
  • the one or more amino acid mutations may be independently selected from substitutions, insertions, deletions, and truncations.
  • the amino acid mutations are amino acid substitutions, and may include conservative and/or non-conservative substitutions. “Conservative substitutions” may be made, for instance, on the basis of similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the amino acid residues involved.
  • the 20 naturally occurring amino acids can be grouped into the following six standard amino acid groups: (1) hydrophobic: Met, Ala, Vai, Leu, lie; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.
  • conservative substitutions are defined as exchanges of an amino acid by another amino acid listed within the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains one negative charge in the so modified polypeptide.
  • glycine and proline may be substituted for one another based on their ability to disrupt a-helices.
  • “non-conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.
  • the substitutions may also include non-classical amino acids (e.g., selenocysteine, pyrrolysine, M-formylmethionine p-alanine, GABA and 5-Aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, y-Abu, s-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosme, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclo
  • Mutations may also be made to the nucleotide sequences of the chimeric proteins by reference to the genetic code, including taking into account codon degeneracy.
  • a chimeric protein is capable of binding human ligand(s)/receptor(s).
  • each extracellular domain (or variant thereof) of the chimeric protein binds to its cognate receptor or ligand with a KD of about 1 nM to about 5 nM, for example, about 1 nM, about 1.5 nM, about 2 nM, about 2.5 nM, about 3 nM, about 3.5 nM, about 4 nM, about 4.5 nM, or about 5 nM.
  • the chimeric protein binds to a cognate receptor or ligand with a KD of about 5 nM to about 15 nM, for example, about 5 nM, about 5.5 nM, about 6 nM, about 6.5 nM, about 7 nM, about 7.5 nM, about 8 nM, about 8.5 nM, about 9 nM, about 9.5 nM, about 10 nM, about 10.5 nM, about 11 nM, about 11.5 nM, about 12 nM, about
  • each extracellular domain (or variant thereof) of the chimeric protein binds to its cognate receptor or ligand with a KD of less than about 1 pM, about 900 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 400 nM, about 300 nM, about 200 nM, about 150 nM, about 130 nM, about 100 nM, about 90 nM, about 80 nM, about 70 nM, about 60 nM, about 55 nM, about 50 nM, about 45 nM, about 40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM, about 15 nM, about 10 nM, or about 5 nM, or about 1 nM (as measured, for example, by surface plasmon resonance or biolayer interferometry).
  • the chimeric protein binds to human CD47 with a KD of about 1 nM to about 5 nM, for example, about 1 nM, about 1 .5 nM, about 2 nM, about 2.5 nM, about 3 nM, about 3.5 nM, about 4 nM, about
  • the chimeric protein binds to human CD47 with a KD of less than about 3 nM, about 2 nM, about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM about 55 pM about 50 pM about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM, about 20 pM, about 15 pM, or about 10 pM, or about 1 pM (as measured, for example, by surface plasmon resonance or biolayer interferometry).
  • the chimeric protein binds to human CD40 with a KD of less than about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM about 55 pM about 50 pM about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM, about 20 pM, about 15 pM, or about 10 pM, or about 1 pM (as measured, for example, by surface plasmon resonance or biolayer interferometry).
  • a variant of an extracellular domain is capable of binding the receptor/ligand of a native extracellular domain.
  • a variant may include one or more mutations in an extracellular domain which do not affect its binding affinity to its receptor/ligand; alternately, the one or more mutations in an extracellular domain may improve binding affinity for the receptor/ligand; or the one or more mutations in an extracellular domain may reduce binding affinity for the receptor/ligand, yet not eliminate binding altogether.
  • the one or more mutations are located outside the binding pocket where the extracellular domain interacts with its receptor/ligand.
  • the one or more mutations are located inside the binding pocket where the extracellular domain interacts with its receptor/ligand, as long as the mutations do not eliminate binding altogether. Based on the skilled artisan’s knowledge and the knowledge in the art regarding receptor-ligand binding, s/he would know which mutations would permit binding and which would eliminate binding.
  • the chimeric protein exhibits enhanced stability and protein half-life.
  • a chimeric protein of the present disclosure may comprise more than two extracellular domains.
  • the chimeric protein may comprise three, four, five, six, seven, eight, nine, ten, or more extracellular domains.
  • a second extracellular domain may be separated from a third extracellular domain via a linker, as disclosed herein.
  • a second extracellular domain may be directly linked (e.g., via a peptide bond) to a third extracellular domain.
  • a chimeric protein includes extracellular domains that are directly linked and extracellular domains that are indirectly linked via a linker, as disclosed herein.
  • the chimeric protein comprises a linker.
  • the linker comprising at least one cysteine residue capable of forming a disulfide bond.
  • the at least one cysteine residue is capable of forming a disulfide bond between a pair (or more) of chimeric proteins.
  • disulfide bond forming is responsible for maintaining a useful multimeric state of chimeric proteins. This allows for efficient production of the chimeric proteins; it allows for desired activity in vitro and in vivo.
  • the linker is a polypeptide selected from a flexible amino acid sequence, an IgG hinge region, or an antibody sequence.
  • the linker is derived from naturally-occurring multi-domain proteins or is an empirical linker as described, for example, in Chichili et al., Protein Sci. 22(2):153-167 (2013); Chen et al., Adv Drug Deliv Rev. 65(10): 1357-1369 (2013), the entire contents of which are hereby incorporated by reference.
  • the linker may be designed using linker designing databases and computer programs such as those described in Chen et al., Adv Drug DelivRev. 65(10): 1357-1369 (2013); and Crasto et al., Protein Eng. 13(5):309-312 (2000), the entire contents of which are hereby incorporated by reference.
  • the linker comprises a polypeptide.
  • the polypeptide is less than about 500 amino acids long, about 450 amino acids long, about 400 amino acids long, about 350 amino acids long, about 300 amino acids long, about 250 amino acids long, about 200 amino acids long, about 150 amino acids long, or about 100 amino acids long.
  • the linker may be less than about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, or about 2 amino acids long.
  • the linker is flexible.
  • the linker is rigid.
  • the linker is substantially comprised of glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycines and serines).
  • the linker comprises a hinge region of an antibody (e.g., of IgG, IgA, IgD, and I g E, inclusive of subclasses (e.g., lgG1 , lgG2, lgG3, and lgG4, and lgA1 , and lgA2)).
  • the hinge region found in IgG, IgA, IgD, and IgE class antibodies, acts as a flexible spacer, allowing the Fab portion to move freely in space.
  • the hinge domains are structurally diverse, varying in both sequence and length among immunoglobulin classes and subclasses.
  • the length and flexibility of the hinge region varies among the IgG subclasses.
  • the hinge region of lgG1 encompasses amino acids 216-231 and, because it is freely flexible, the Fab fragments can rotate about their axes of symmetry and move within a sphere centered at the first of two inter-heavy chain disulfide bridges.
  • lgG2 has a shorter hinge than lgG1 , with 12 amino acid residues and four disulfide bridges.
  • the hinge region of lgG2 lacks a glycine residue, is relatively short, and contains a rigid poly-proline double helix, stabilized by extra inter-heavy chain disulfide bridges. These properties restrict the flexibility of the lgG2 molecule.
  • I gG3 differs from the other subclasses by its unique extended hinge region (about four times as long as the I gG 1 hinge), containing 62 amino acids (including 21 prolines and 11 cysteines), forming an inflexible poly-proline double helix.
  • the Fab fragments are relatively far away from the Fc fragment, giving the molecule a greater flexibility.
  • the elongated hinge in lgG3 is also responsible for its higher molecular weight compared to the other subclasses.
  • the hinge region of I gG4 is shorter than that of lgG1 and its flexibility is intermediate between that of lgG1 and lgG2.
  • the linker may be derived from human lgG4 and contain one or more mutations to enhance dimerization (including S228P) or FcRn binding.
  • the immunoglobulin hinge region can be further subdivided functionally into three regions: the upper hinge region, the core region, and the lower hinge region.
  • the upper hinge region includes amino acids from the carboxyl end of CHI to the first residue in the hinge that restricts motion, generally the first cysteine residue that forms an interchain disulfide bond between the two heavy chains.
  • the length of the upper hinge region correlates with the segmental flexibility of the antibody.
  • the core hinge region contains the inter-heavy chain disulfide bridges, and the lower hinge region joins the amino terminal end of the CH2 domain and includes residues in CH2. Id.
  • the core hinge region of wild-type human lgG1 contains the sequence CPPC (SEQ ID NO: 24) which, when dimerized by disulfide bond formation, results in a cyclic octapeptide believed to act as a pivot, thus conferring flexibility.
  • the present linker comprises, one, or two, or three of the upper hinge region, the core region, and the lower hinge region of any antibody e.g., of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g., lgG1 , lgG2, lgG3, and lgG4, and lgA1 and lgA2)).
  • the hinge region may also contain one or more glycosylation sites, which include a number of structurally distinct types of sites for carbohydrate attachment.
  • lgA1 contains five glycosylation sites within a 17-amino-acid segment of the hinge region, conferring resistance of the hinge region polypeptide to intestinal proteases, considered an advantageous property for a secretory immunoglobulin.
  • the linker of the present disclosure comprises one or more glycosylation sites.
  • the linker comprises an Fc domain of an antibody (e.g., of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g., lgG1, lgG2, lgG3, and lgG4, and lgA1 and lgA2)).
  • an antibody e.g., of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g., lgG1, lgG2, lgG3, and lgG4, and lgA1 and lgA2)).
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from lgG4. In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from a human I gG4. In embodiments, the linker comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 3 (e.g., at least 95% identical to the amino acid sequence of SEQ ID NO: 2.).
  • the linker comprises one or more joining linkers, such joining linkers independently selected from SEQ ID NOs: 4-50 (or a variant thereof). In embodiments, the linker comprises two or more joining linkers each joining linker independently selected from SEQ ID NOs: 4-50 (or a variant thereof); wherein one joining linker is N terminal to the hinge-CH2-CH3 Fc domain and another joining linker is C terminal to the hinge-CH2-CH3 Fc domain.
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from a human lgG1 antibody.
  • the Fc domain exhibits increased affinity for and enhanced binding to the neonatal Fc receptor (FcRn).
  • the Fc domain includes one or more mutations that increases the affinity and enhances binding to FcRn. Without wishing to be bound by theory, it is believed that increased affinity and enhanced binding to FcRn increases the in vivo half-life of the present chimeric proteins.
  • the Fc domain in a linker contains one or more amino acid substitutions at amino acid residue 250, 252, 254, 256, 308, 309, 311 , 416, 428, 433, or 434 (in accordance with Kabat numbering, as in as in Kabat, etal., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) expressly incorporated herein by reference), or equivalents thereof.
  • the amino acid substitution at amino acid residue 250 is a substitution with glutamine.
  • the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan, or threonine.
  • the amino acid substitution at amino acid residue 254 is a substitution with threonine.
  • the amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamic acid, aspartic acid, or threonine.
  • the amino acid substitution at amino acid residue 308 is a substitution with threonine.
  • the amino acid substitution at amino acid residue 309 is a substitution with proline.
  • the amino acid substitution at amino acid residue 311 is a substitution with serine.
  • the amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine, or glycine.
  • the amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine.
  • the amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine.
  • the amino acid substitution at amino acid residue 389 is a substitution with proline, serine, or asparagine.
  • the amino acid substitution at amino acid residue 416 is a substitution with serine.
  • the amino acid substitution at amino acid residue 428 is a substitution with leucine.
  • the amino acid substitution at amino acid residue 433 is a substitution with arginine, serine, isoleucine, proline, or glutamine.
  • the amino acid substitution at amino acid residue 434 is a substitution with histidine, phenylalanine, or tyrosine.
  • the Fc domain linker (e.g., comprising an IgG constant region) comprises one or more mutations such as substitutions at amino acid residue 252, 254, 256, 433, 434, or 436 (in accordance with Kabat numbering, as in as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) expressly incorporated herein by reference).
  • the IgG constant region includes a triple M252Y/S254T/T256E mutation or YTE mutation.
  • the IgG constant region includes a triple H433K/N434F/Y436H mutation or KFH mutation.
  • the IgG constant region includes an YTE and KFH mutation in combination.
  • the linker comprises an IgG constant region that contains one or more mutations at amino acid residues 250, 253, 307, 310, 380, 428, 433, 434, and 435 (in accordance with Kabat numbering, as in as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) expressly incorporated herein by reference).
  • Illustrative mutations include T250Q, M428L, T307A, E380A, I253A, H310A, M428L, H433K, N434A, N434F, N434S, and H435A.
  • the IgG constant region comprises a M428L/N434S mutation or LS mutation. In embodiments, the IgG constant region comprises a T250Q/M428L mutation or QL mutation. In embodiments, the IgG constant region comprises an N434A mutation. In embodiments, the IgG constant region comprises a T307A/E380A/N434A mutation or AAA mutation. In embodiments, the IgG constant region comprises an I253A/H310A/H435A mutation or IHH mutation. In embodiments, the IgG constant region comprises a H433K/N434F mutation.
  • the IgG constant region comprises a M252Y/S254T/T256E and a H433K/N434F mutation in combination. Additional exemplary mutations in the IgG constant region are described, for example, in Robbie, et al., Antimicrobial Agents and Chemotherapy 57(12):6147-6153 (2013); Dall’Acqua ef al., Journal Biol Chem 281 (33):23514-24 (2006); Dall’Acqua et al., Journal of Immunology 169:5171-80 (2002); Ko et al. Nature 514:642-645 (2014); Grevys et al. Journal of Immunology 194(11):5497-508 (2015); and U.S. Patent No. 7,083,784, the entire contents of which are hereby incorporated by reference.
  • An illustrative Fc stabilizing mutant is S228P.
  • Illustrative Fc half-life extending mutants are T250Q, M428L, V308T, L309P, and Q311 S and the present linkers may comprise 1 , or 2, or 3, or 4, or 5 of these mutants.
  • the chimeric protein binds to FcRn with high affinity.
  • the chimeric protein may bind to FcRn with a KD of about 1 nM to about 80 nM.
  • the chimeric protein may bind to FcRn with a KD of about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 35 nM, about 40 nM, about 45 nM, about 50 nM, about 55 nM, about 60 nM, about 65 nM, about 70 nM, about 71 nM, about 72 nM, about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 n
  • the chimeric protein may bind to FcRn with a KD of about 9 nM. In embodiments, the chimeric protein does not substantially bind to other Fc receptors (/.e., other than FcRn) with effector function.
  • the Fc domain in a linker has the amino acid sequence of SEQ ID NO: 1 (see Table 1, below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.
  • mutations are made to SEQ ID NO: 1 to increase stability and/or half-life.
  • the Fc domain in a linker comprises the amino acid sequence of SEQ ID NO: 2 (see Table 1, below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.
  • the Fc domain in a linker comprises the amino acid sequence of SEQ ID NO: 3 (see Table 1, below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.
  • one or more joining linkers may be employed to connect an Fc domain in a linker (e.g., one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto) and the extracellular domains.
  • a linker e.g., one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto
  • any one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof may connect an extracellular domain as disclosed herein and an Fc domain in a linker as disclosed herein.
  • any one of SEQ ID NOs: 4 to 50, 62 and 63, or variants thereof are located between an extracellular domain as disclosed herein and an Fc domain as disclosed herein.
  • the presentchimeric proteins may comprise variants of the joining linkers disclosed in Table 1, below.
  • a linker may have at least about 60%, or at least about 61 %, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71 %, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81 %, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or
  • first and second joining linkers may be different, or they may be the same.
  • linker comprising at least a part of an Fc domain in a chimeric protein, helps avoid formation of insoluble and, likely, non-functional protein concatemers and/or aggregates. This is in part due to the presence of cysteines in the Fc domain which are capable of forming disulfide bonds between chimeric proteins.
  • a chimeric protein may comprise one or more joining linkers, as disclosed herein, and lack a Fc domain linker, as disclosed herein.
  • first and/or second joining linkers are independently selected from the amino acid sequences of SEQ ID NOs: 4 to 50, 62 and 63 and are provided in Table 1 below:
  • the joining linker substantially comprises glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycines and serines).
  • the joining linker is (Gly4Ser) n , where n is from about 1 to about 8, e.g., 1 , 2, 3, 4, 5, 6, 7, or 8 (SEQ ID NO: 25 to SEQ ID NO: 9, respectively).
  • the joining linker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 33).
  • X designating any amino acid, e.g., Ala, Lys, or Glu.
  • the joining linker is GGS.
  • a joining linker has the sequence (Gly)n where n is any number from 1 to 100, for example: (Gly)s (SEQ ID NO: 34) and (Gly) 6 (SEQ ID NO: 35).
  • the joining linker is one or more of GGGSE (SEQ ID NO: 47), GSESG (SEQ ID NO: 48), GSEGS (SEQ ID NO: 49), GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS (SEQ ID NO: 50), and a joining linker of randomly placed G, S, and E every 4 amino acid intervals.
  • the chimeric protein comprises a joining linker comprising the amino acid sequence of SEQ ID NO: 5 and/or SEQ ID NO: 7.
  • a chimeric protein comprises an extracellular domain (ECD) of CD172a (SIRPa), one joining linker preceding an Fc domain, a second joining linker following the Fc domain, and an ECD of CD40L
  • the chimeric protein may comprise the following structure:
  • a chimeric protein comprises a modular linker as shown in Table 2:
  • the present chimeric proteins may comprise variants of the modular linkers disclosed in Table 2, above.
  • a linker may have at least about 60%, or at least about 61 %, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71 %, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about
  • the linker may be flexible, including without limitation highly flexible. In embodiments, the linker may be rigid, including without limitation a rigid alpha helix. Characteristics of illustrative joining linkers is shown below in Table 3:
  • the linker may be functional.
  • the linker may function to improve the folding and/or stability, improve the expression, improve the pharmacokinetics, and/or improve the bioactivity of the present chimeric protein.
  • the linker may function to target the chimeric protein to a particular cell type or location.
  • a chimeric protein comprises only one joining linkers.
  • a chimeric protein lacks joining linkers.
  • the linker is a synthetic linker such as polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • a chimeric protein has a first domain which is sterically capable of binding its ligand/receptor and/or the second domain which is sterically capable of binding its ligand/receptor.
  • first domain which is sterically capable of binding its ligand/receptor
  • second domain which is sterically capable of binding its ligand/receptor.
  • This flexibility and/or physical distance (which is referred to as “slack”) may be normally present in the extracellular domain(s), normally present in the linker, and/or normally present in the chimeric protein (as a whole).
  • an amino acid sequence may be added to one or more extracellular domains and/or to the linker to provide the slack needed to avoid steric hindrance.
  • Any amino acid sequence that provides slack may be added.
  • the added amino acid sequence comprises the sequence (Gly)n where n is any number from 1 to 100. Additional examples of addable amino acid sequence include the joining linkers described in Table 1 and Table 3.
  • a polyethylene glycol (PEG) linker may be added between an extracellular domain and a linker to provide the slack needed to avoid steric hindrance. Such PEG linkers are well known in the art.
  • a chimeric protein of the present disclosure comprises the extracellular domain of human CD172a (SIRPo) (or a variant thereof), a linker, and the extracellular domain of human CD40L (or a variant thereof).
  • the linker comprises a hinge-CH2-CH3 Fc domain, e.g., from an lgG1 or from lgG4, including human lgG1 or lgG4.
  • a chimeric protein of the present disclosure comprises the extracellular domain of human CD172a (SIRPo) (or a variant thereof), linker comprising a hinge-CH2-CH3 Fc domain, and the extracellular domain of human CD40L (or a variant thereof).
  • Such a chimeric protein may be referred to herein as “hCD172a (SIRPa)-Fc-CD40L” or “SL-172154”.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the dose of the chimeric protein is administered at a dosage of at least about 0.3 mg/kg.
  • the chimeric protein is administered at the dosage of about 1 mg/kg.
  • the chimeric protein is administered at the dosage of about 3 mg/kg.
  • the chimeric protein is
  • the human subject suffers from or is suspected to suffer from an advanced solid tumor or a lymphoma.
  • the human subject suffers from or is suspected to suffer from a cancer is selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the human subject has failed one or more platinum-based therapies.
  • the human subject is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • the human subject has failed one or more platinum-based therapies.
  • the human subject is ineligible for a further platinum therapy.
  • the human subject is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • chimeric proteins disclosed herein including the CD172a (SIRPa)-Fc-CD40L chimeric protein e.g., SEQ ID NO: 59 or SEQ ID NO: 61), finds use in methods for treating both advanced solid tumors and advanced lymphomas.
  • SIRPa CD172a
  • Fc-CD40L chimeric protein e.g., SEQ ID NO: 59 or SEQ ID NO: 61
  • tumor types include melanoma, non-small cell lung cancer (squamous, adeno, adenosquamous), urothelial cancer, renal cell cancer, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of the anus, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the skin, and microsatellite instability high or mismatch repair deficient solid tumors excluding central nervous system (CNS) tumors.
  • Other tumors of interest include Hodgkin’s lymphoma (HL), diffuse large B cell lymphoma, acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS).
  • HL Hodgkin’s lymphoma
  • AML acute myeloid leukemia
  • HR-MDS high-risk myelodysplastic syndromes
  • the cancer comprises an advanced solid tumor (local and/or metastatic).
  • the human subject has a cancer, wherein the cancer being treated is characterized by having macrophages in the tumor microenvironment and/or having tumor cells that are CD47+ cells in the tumor.
  • the administration of the SIRPa- Fc-CD40L chimeric protein blocks the “don’t eat me” signal of a tumor cell and /or stimulates an “eat me” signal.
  • the therapy with the SIRPa-Fc-CD40L chimeric protein stimulates macrophages to phagocytize tumor cells and effectively present the tumor antigens of phagocytized tumor cells to T cells.
  • the cancer is a solid cancer. In embodiments, the cancer is a solid tumor. In embodiments, the cancer is a metastatic cancer. In embodiments, the cancer is a hematological cancer. In embodiments, the cancer expresses CD47.
  • the cancer comprises an advanced lymphoma. In embodiments, the cancer comprises acute myeloid leukemia (AML). In embodiments, the cancer comprises p53 mutant AML. In embodiments, the cancer comprises a high-risk myelodysplastic syndrome (HR-MDS).
  • AML acute myeloid leukemia
  • HR-MDS high-risk myelodysplastic syndrome
  • aspects of the present disclosure provide methods of treating cancer.
  • the methods comprise a step of administering to a subject in need thereof an effective amount of a chimeric protein, e.g., in a pharmaceutical composition, as disclosed herein.
  • the chimeric protein of the present disclosure comprises an extracellular domain of human CD172a (SIRPa), which disrupts, blocks, reduces, inhibits, and/or sequesters the transmission of immune inhibitory signals, e.g., originating from a cancer cell that is attempting to avoid its detection and/or destruction, and an extracellular domain of human CD40L, which enhances, increases, and/or stimulates the transmission of an immune stimulatory signal to an anti-cancer immune cell.
  • SIRPa extracellular domain of human CD172a
  • the simultaneous binding of the extracellular domain of CD172a (SIRPa) to its ligand/receptor and the binding of the extracellular domain of CD40L with its receptor will prevent the transmission of an immunosuppressive signal from the cancer cell and will have stimulate immune activity in an immune system cell.
  • chimeric proteins of the present disclosure are capable of treating cancer via two distinct mechanisms.
  • the present disclosure pertains to cancers and/or tumors; for example, the treatment or prevention of cancers and/or tumors.
  • the treatment of cancer involves, in embodiments, modulating the immune system with the present chimeric proteins to favor of increasing or activating immune stimulatory signals.
  • the method reduces the amount and/or activity of regulatory T cells (Tregs) as compared to untreated subjects or subjects treated with antibodies directed to CD172a (SIRPo), CD40L, and/or their respective ligands or receptors.
  • Tregs regulatory T cells
  • the method increases priming of effector T cells in draining lymph nodes of the subject as compared to untreated subjects or subjects treated with antibodies directed to CD172a (SIRPo), CD40L, and/or their respective ligands or receptors.
  • the method causes an overall decrease in immunosuppressive cells and a shift toward a more inflammatory tumor environment as compared to untreated subjects or subjects treated with antibodies directed to the CD172a (SIRPo), CD40L, and/or their respective ligands or receptors.
  • the present chimeric proteins are capable of, or can be used in methods comprising, modulating the amplitude of an immune response, e.g., modulating the level of effector output.
  • the present chimeric proteins alter the extent of immune stimulation as compared to immune inhibition to increase the amplitude of a T cell response, including, without limitation, stimulating increased levels of cytokine production, proliferation or target killing potential.
  • the patient’s T cells are activated and/or stimulated by the chimeric protein, with the activated T cells being capable of dividing and/or secreting cytokines.
  • Cancers or tumors refer to an uncontrolled growth of cells and/or abnormal increased cell survival and/or inhibition of apoptosis which interferes with the normal functioning of the bodily organs and systems. Included are benign and malignant cancers, polyps, hyperplasia, as well as dormant tumors or micrometastases. Also, included are cells having abnormal proliferation that is not impeded by the immune system (e.g., virus infected cells).
  • the cancer may be a primary cancer or a metastatic cancer.
  • the primary cancer may be an area of cancer cells at an originating site that becomes clinically detectable and may be a primary tumor.
  • the metastatic cancer may be the spread of a disease from one organ or part to another non-adjacent organ or part.
  • the metastatic cancer may be caused by a cancer cell that acquires the ability to penetrate and infiltrate surrounding normal tissues in a local area, forming a new tumor, which may be a local metastasis.
  • the cancer may also be caused by a cancer cell that acquires the ability to penetrate the walls of lymphatic and/or blood vessels, after which the cancer cell is able to circulate through the bloodstream (thereby being a circulating tumor cell) to other sites and tissues in the body.
  • the cancer may be due to a process such as lymphatic or hematogenous spread.
  • the cancer may also be caused by a tumor cell that comes to rest at another site, re-penetrates through the vessel or walls, continues to multiply, and eventually forms another clinically detectable tumor.
  • the cancer may be this new tumor, which may be a metastatic (or secondary) tumor.
  • the cancer may be caused by tumor cells that have metastasized, which may be a secondary or metastatic tumor.
  • the cells of the tumor may be like those in the original tumor.
  • the secondary tumor while present in the liver, is made up of abnormal breast or colon cells, not of abnormal liver cells.
  • the tumor in the liver may thus be a metastatic breast cancer or a metastatic colon cancer, not liver cancer.
  • the cancer may have an origin from any tissue.
  • the cancer may originate from melanoma, colon, breast, or prostate, and thus may be made up of cells that were originally skin, colon, breast, or prostate, respectively.
  • the cancer may also be a hematological malignancy, which may be leukemia or lymphoma.
  • the cancer may invade a tissue such as liver, lung, bladder, or intestinal.
  • the chimeric protein is used to treat a subject that has a treatment-refractory cancer. In embodiments, the chimeric protein is used to treat a subject that is refractory to one or more immune- modulating agents. For example, in embodiments, the chimeric protein is used to treat a subject that presents no response to treatment, or whose disease progresses, after 12 weeks or so of treatment.
  • the subject is refractory to one or more CD172a (SIRPa) and/or CD47 agents, including, for example, Magrolimab (5F9), Hu5F9-G4, CC-90002, Ti-061, SRF231 , TTI-621 , TTI-622, or ALX148 refractory patients.
  • the subject is refractory to an anti-CTLA-4 agent, e.g., ipilimumab (YERVOY)-refractory patients (e.g., melanoma patients).
  • an anti-CTLA-4 agent e.g., ipilimumab (YERVOY)-refractory patients (e.g., melanoma patients).
  • YERVOY ipilimumab
  • the present disclosure provides methods of cancer treatment that rescue patients that are non-responsive to various therapies, including monotherapy of one or more immune-modulating agents.
  • the present disclosure provides chimeric proteins which target a cell or tissue within the tumor microenvironment.
  • the cell or tissue within the tumor microenvironment expresses one or more targets or binding partners of the chimeric protein.
  • the tumor microenvironment refers to the cellular milieu, including cells, secreted proteins, physiological small molecules, and blood vessels in which the tumor exists.
  • the cells or tissue within the tumor microenvironment are one or more of: tumor vasculature; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPC); cancer-associated fibroblasts; pericytes; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen presenting cells; T-cells; regulatory T cells; macrophages; neutrophils; and other immune cells located proximal to a tumor.
  • the present chimeric protein targets a cancer cell.
  • the cancer cell expresses one or more of targets or binding partners of the chimeric protein.
  • costimulatory and co-inhibitory signals Two major families of costimulatory molecules include the B7 and the tumor necrosis factor (TNF) families. These molecules bind to receptors on T cells belonging to the CD28 or TNF receptor families, respectively. Many well-defined co-inhibitors and their receptors belong to the B7 and CD28 families.
  • B7 and CD28 families Two major families of costimulatory molecules include the B7 and the tumor necrosis factor (TNF) families. These molecules bind to receptors on T cells belonging to the CD28 or TNF receptor families, respectively. Many well-defined co-inhibitors and their receptors belong to the B7 and CD28 families.
  • TNF tumor necrosis factor
  • an immune stimulatory signal refers to a signal that enhances an immune response.
  • such signals may enhance antitumor immunity.
  • immune stimulatory signal may be identified by directly stimulating proliferation, cytokine production, killing activity, or phagocytic activity of leukocytes.
  • a chimeric protein may directly stimulate the proliferation and cytokine production of individual T cell subsets.
  • Another example includes direct stimulation of an immune inhibitory cell with through a receptor that inhibits the activity of such an immune suppressor cell. This would include, for example, stimulation of CD4+FoxP3+ regulatory T cells, which would reduce the ability of those regulatory T cells to suppress the proliferation of conventional CD4+ or CD8+ T cells.
  • the chimeric protein causes activation of the lymphoid cell and/or production of pro-inflammatory cytokines or chemokines to further stimulate an immune response, optionally within a tumor.
  • the present chimeric proteins are capable of, or find use in methods involving, enhancing, restoring, promoting and/or stimulating immune modulation.
  • the present chimeric proteins described herein restore, promote and/or stimulate the activity or activation of one or more immune cells against tumor cells including, but not limited to: T cells, cytotoxic T lymphocytes, T helper cells, natural killer (NK) cells, natural killer T (NKT) cells, anti-tumor macrophages (e.g., M1 macrophages), B cells, and dendritic cells.
  • the present chimeric proteins enhance, restore, promote and/or stimulate the activity and/or activation of T cells, including, by way of a non-limiting example, activating and/or stimulating one or more T- cell intrinsic signals, including a pro-survival signal; an autocrine or paracrine growth signal; a p38 MAPK-, ERK-, STAT-, JAK-, AKT- or PI3K-mediated signal; an anti-apoptotic signal; and/or a signal promoting and/or necessary for one or more of: pro-inflammatory cytokine production or T cell migration or T cell tumor infiltration.
  • T- cell intrinsic signals including a pro-survival signal; an autocrine or paracrine growth signal; a p38 MAPK-, ERK-, STAT-, JAK-, AKT- or PI3K-mediated signal; an anti-apoptotic signal; and/or a signal promoting and/or necessary for one or more of: pro-inflammatory cytokine production or T cell
  • the present chimeric proteins are capable of, or find use in methods involving, causing an increase of one or more of T cells (including without limitation cytotoxic T lymphocytes, T helper cells, natural killer T (NKT) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, and macrophages (e.g., one or more of M1 and M2) into a tumor or the tumor microenvironment.
  • T cells including without limitation cytotoxic T lymphocytes, T helper cells, natural killer T (NKT) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, and macrophages (e.g., one or more of M1 and M2) into a tumor or the tumor microenvironment.
  • T cells including without limitation cytotoxic T lymphocytes, T helper cells, natural killer T (NKT) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, dend
  • the present chimeric protein induces CD19 expression and/or increases the number of CD19 positive cells (e.g., CD19 positive B cells). In embodiments, the present chimeric protein induces IL-15Roc expression and/or increases the number of I L-15Roc positive cells (e.g., I L-15Roc positive dendritic cells).
  • the present chimeric proteins are capable of, or find use in methods involving, inhibiting and/or causing a decrease in immunosuppressive cells (e.g., myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), tumor associated neutrophils (TANs), M2 macrophages, and tumor associated macrophages (TAMs)), and particularly within the tumor and/or tumor microenvironment (TME).
  • immunosuppressive cells e.g., myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), tumor associated neutrophils (TANs), M2 macrophages, and tumor associated macrophages (TAMs)
  • TME tumor associated macrophages
  • the present therapies may alter the ratio of M1 versus M2 macrophages in the tumor site and/or TME to favor M1 macrophages.
  • the SIRPa- Fc-CD40L chimeric protein suppresses/reduces/eliminates a “don’t eat me” signal via Sirpl a/CD47 from being transmitted on tumor cells.
  • the SIRPa- Fc-CD40L chimeric protein makes a tumor more likely to be attacked by the immune system of the subject.
  • the SIRPa- Fc-CD40L chimeric protein makes a tumor more likely to be attacked by the innate immune system of the subject.
  • the SIRPa- Fc- CD40L chimeric protein makes a tumor more likely to be attacked by the adaptive immune system of the subject.
  • the SIRPa- Fc-CD40L chimeric protein can suppress/reduce/eliminate binding of tumor-overexpressed CD47 with phagocyte-expressed SIRPa to permit phagocytic removal of cancer cells and/or immunogenic processing of tumor antigens by macrophages and/or dendritic cells.
  • the administration of the SIRPa- Fc-CD40L chimeric protein blocks the “don’t eat me” signal of a tumor cell and /or stimulates an “eat me” signal.
  • the therapy with the SIRPa-Fc-CD40L chimeric protein stimulates macrophages to phagocytize tumor cells and effectively present the tumor antigens of phagocytized tumor cells to T cells.
  • the present chimeric proteins are able to increase the serum levels of various cytokines including, but not limited to, one or more of IFNy, TNFa, IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, and IL-22.
  • the present chimeric proteins are capable of enhancing IL-2, IL-4, IL-5, IL-10, IL- 13, IL-17A, IL-22, or IFNy in the serum of a treated subject.
  • the present chimeric proteins do not increase the serum levels of certain cytokines.
  • the present chimeric proteins do not increase the serum levels of IL-6 and/ or TNFa.
  • the present chimeric proteins do not increase the serum levels of IL-6 and/ or TNFa in the serum of a treated subject. In embodiments, the present chimeric proteins do not increase the serum levels of IL-6 and/ or TNFa in the serum of a treated subject, while increasing the levels of other cytokines, including but not limited to, CCL2, IL-8 and CXCL9 in serum of a treated subject. Detection of such a cytokine response may provide a method to determine the optimal dosing regimen for the indicated chimeric protein.
  • the chimeric protein is capable of increasing or preventing a decrease in a sub-population of CD4+ and/or CD8+T cells.
  • the chimeric protein is capable of enhancing tumor killing activity by T cells.
  • the chimeric protein activates the human subject’s T cells when bound by the CD40L domain of the chimeric protein and (a) one or more tumor cells are prevented from transmitting an immunosuppressive signal when bound by the first domain of the chimeric protein, (b) a quantifiable cytokine response in the peripheral blood of the subject is achieved, and/or (c) tumor growth is reduced in the subject in need thereof as compared to a subject treated with CD40 agonist antibodies and/or CD47 blocking antibodies.
  • the present chimeric proteins inhibit, block and/or reduce cell death of an anti-tumor CD8+ and/or CD4+ T cell; or stimulate, induce, and/or increase cell death of a pro-tumor T cell.
  • T cell exhaustion is a state of T cell dysfunction characterized by progressive loss of proliferative and effector functions, culminating in clonal deletion.
  • a pro-tumor T cell refers to a state of T cell dysfunction that arises during many chronic infections, inflammatory diseases, and cancer. This dysfunction is defined by poor proliferative and/or effector functions, sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. Exhaustion prevents optimal control of infection and tumors.
  • Illustrative pro-tumor T cells include, but are not limited to, Tregs, CD4+ and/or CD8+ T cells expressing one or more checkpoint inhibitory receptors, Th2 cells and Th17 cells.
  • Checkpoint inhibitory receptors refer to receptors expressed on immune cells that prevent or inhibit uncontrolled immune responses.
  • an anti-tumor CD8+ and/or CD4+ T cell refers to T cells that can mount an immune response to a tumor.
  • the present chimeric proteins are capable of, and can be used in methods comprising, increasing a ratio of effector T cells to regulatory T cells.
  • Illustrative effector T cells include ICOS + effector T cells; cytotoxic T cells e.g., ap TCR, CD3 + , CD8 + , CD45RO+); CD4 + effector T cells (e.g., a0 TCR, CD3 + , CD4 + , CCR7+, CD62Lhi, I L 7R/CD127 ); CD8 + effector T cells (e.g., ap TCR, CD3 + , CD8 + , CCR7+, CD62Lhi, IL7R/CD127+); effector memory T cells (e.g., CD62Llow, CD44 + , TCR, CD3 + , IL 7R/CD127*, IL-15R+, CCR7low); central memory T cells (e.g., CCR7 + , CD62L + ,
  • Illustrative regulatory T cells include ICOS + regulatory T cells, CD4 + CD25 + FOXP3 + regulatory T cells, CD4 + CD25 + regulatory T cells, CD4+CD25 regulatory T cells, CD4 + CD25high regulatory T cells, TIM-3 + CD172a (SI RPa) + regulatory T cells, lymphocyte activation gene-3 (LAG-3) + regulatory T cells, CTLA-4/CD152 + regulatory T cells, neuropilin-1 (Nrp-1) + regulatory T cells, CCR4 + CCR8 + regulatory T cells, CD62L (L-selectin) + regulatory T cells, CD45RBIow regulatory T cells, CD127low regulatory T cells, LRRC32/GARP+ regulatory T cells, CD39 + regulatory T cells, GITR + regulatory T cells, LAP + regulatory T cells, 1 B11 + regulatory T cells, BTLA + regulatory T cells, type 1 regulatory T cells (Tr1 cells), T helper type 3 (Th3) cells, regulatory cell of natural killer T cell phenotype (NKTregs
  • the chimeric protein of the invention causes an increase in effectorT cells (e.g., CD4+CD25- T cells). In embodiments, the chimeric protein causes a decrease in regulatory T cells (e.g., CD4CD25+T cells).
  • the chimeric protein generates a memory response which may, e.g., be capable of preventing relapse or protecting the animal from a recurrence and/or preventing, or reducing the likelihood of, metastasis.
  • a memory response which may, e.g., be capable of preventing relapse or protecting the animal from a recurrence and/or preventing, or reducing the likelihood of, metastasis.
  • an animal treated with the chimeric protein is later able to attack tumor cells and/or prevent development of tumors when rechallenged after an initial treatment with the chimeric protein.
  • a chimeric protein of the present disclosure stimulates both active tumor destruction and also immune recognition of tumor antigens, which are essential in programming a memory response capable of preventing relapse.
  • the chimeric protein is capable of causing activation of antigen presenting cells. In embodiments, the chimeric protein is capable enhancing the ability of antigen presenting cells to present antigen.
  • the present chimeric proteins are capable of, and can be used in methods comprising, transiently stimulating effector T cells for longer than about 12 hours, about 24 hours, about 48 hours, about 72 hours or about 96 hours or about 1 week or about 2 weeks.
  • the transient stimulation of effector T cells occurs substantially in a patient’s bloodstream or in a particular tissue/location including lymphoid tissues such as for example, the bone marrow, lymph-node, spleen, thymus, mucosa-associated lymphoid tissue (MALT), non-lymphoid tissues, or in the tumor microenvironment.
  • lymphoid tissues such as for example, the bone marrow, lymph-node, spleen, thymus, mucosa-associated lymphoid tissue (MALT), non-lymphoid tissues, or in the tumor microenvironment.
  • the present chimeric protein unexpectedly provides binding of the extracellular domain components to their respective binding partners with slow off rates (Kd or Kotf). In embodiments, this provides an unexpectedly long interaction of the receptor to ligand and vice versa. Such an effect allows for a longer positive signal effect, e.g., increase in or activation of immune stimulatory signals.
  • the present chimeric protein e.g., via the long off rate binding allows sufficient signal transmission to provide immune cell proliferation, allow for anti-tumor attack, allows sufficient signal transmission to provide release of stimulatory signals, e.g., cytokines.
  • the chimeric protein is capable of forming a stable synapse between cells.
  • the stable synapse of cells promoted by the chimeric proteins provides spatial orientation to favor tumor reduction - such as positioning the T cells to attack tumor cells and/or sterically preventing the tumor cell from delivering negative signals, including negative signals beyond those masked by the chimeric protein of the invention.
  • this provides longer on-target e.g., intratumoral) half-life (ti/2) as compared to serum ti/2 of the chimeric proteins.
  • Such properties could have the combined advantage of reducing off-target toxicities associated with systemic distribution of the chimeric proteins.
  • the chimeric protein is capable of providing a sustained immunomodulatory effect.
  • the present chimeric proteins provide synergistic therapeutic effects (e.g., anti-tumor effects) as it allows for improved site-specific interplay of two immunotherapy agents.
  • the present chimeric proteins provide the potential for reducing off-site and/or systemic toxicity.
  • the presentchimeric protein exhibits enhanced safety profiles. In embodiments, the present chimeric protein exhibits reduced toxicity profiles. For example, administration of the present chimeric proteins may result in reduced side effects such as one or more of diarrhea, inflammation (e.g., of the gut), or weight loss, which occur following administration of antibodies directed to the ligand(s)/receptor(s) targeted by the extracellular domains of the present chimeric proteins. In embodiments, the present chimeric protein provides improved safety, as compared to antibodies directed to the ligand(s)/receptor(s) targeted by the extracellular domains of the present chimeric proteins, yet, without sacrificing efficacy.
  • the present chimeric proteins provide reduced side-effects, e.g., Gl complications, relative to current immunotherapies, e.g., antibodies directed to ligand(s)/receptor(s) targeted by the extracellular domains of the present chimeric proteins.
  • Gl complications include abdominal pain, appetite loss, autoimmune effects, constipation, cramping, dehydration, diarrhea, eating problems, fatigue, flatulence, fluid in the abdomen or ascites, gastrointestinal (Gl) dysbiosis, Gl mucositis, inflammatory bowel disease, irritable bowel syndrome (IBS-D and IBS-C), nausea, pain, stool or urine changes, ulcerative colitis, vomiting, weight gain from retaining fluid, and/or weakness.
  • aspects of the present disclosure include a pharmaceutical composition comprising a therapeutically effective amount of a chimeric protein as disclosed herein.
  • Any chimeric protein disclosed herein may be used in a pharmaceutical composition.
  • a chimeric protein disclosed herein is provided as a sterile frozen solution in a vial or as a sterile liquid solution in a vial.
  • a drug product comprising a chimeric protein disclosed herein comprises a sterile-filtered, formulated chimeric protein disclosed herein solution filled into a 10 mL single-use glass vial stoppered with a Flurotec® rubber stopper and sealed with an aluminum flip off seal.
  • a chimeric protein disclosed herein is formulated at between about 10 mg/mL to about 30 mg/mL, e.g., about 20 mg/mL in between about 30 mM to about 70 mM L-histidine, e.g., about 50 mM L-histidine and between about 125 mM and about 400 mM sucrose, e.g., about 250 mM sucrose in water for injection.
  • each vial contains about 1 mL of drug product or about 20 mg of a chimeric protein disclosed herein.
  • the chimeric proteins disclosed herein can possess a sufficiently basic functional group, which can react with an inorganic or organic acid, or a carboxyl group, which can react with an inorganic or organic base, to form a pharmaceutically acceptable salt.
  • a pharmaceutically-acceptable acid addition salt is formed from a pharmaceutically acceptable acid, as is well known in the art.
  • Such salts include the pharmaceutically acceptable salts listed in, for example, Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.
  • compositions disclosed herein are in the form of a pharmaceutically acceptable salt.
  • any chimeric protein disclosed herein can be administered to a subject as a component of a composition, e.g., pharmaceutical composition, which comprises a pharmaceutically acceptable carrier or vehicle.
  • a pharmaceutical composition which comprises a pharmaceutically acceptable carrier or vehicle.
  • Such pharmaceutical compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration.
  • Pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • the pharmaceutical excipients can be, for example, saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
  • the pharmaceutically acceptable excipients are sterile when administered to a subject.
  • Water is a useful excipient when any agent disclosed herein is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions.
  • Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Any agent disclosed herein, if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the compositions e.g., pharmaceutical compositions, disclosed herein are resuspended in a saline buffer (including, without limitation TBS, PBS, and the like).
  • the chimeric proteins may by conjugated and/or fused with another agent to extend half-life or otherwise improve pharmacodynamic and pharmacokinetic properties.
  • the chimeric proteins may be fused or conjugated with one or more of PEG, XTEN (e.g., as rPEG), polysialic acid (POLYXEN), albumin (e.g., human serum albumin or HAS), elastin-like protein (ELP), PAS, HAP, GLK, CTP, transferrin, and the like.
  • each of the individual chimeric proteins is fused to one or more of the agents described in Strohl, BioDrugs 29(4):215— 239 (2015), the entire contents of which are hereby incorporated by reference.
  • the present disclosure includes the disclosed chimeric protein in various formulations of pharmaceutical composition.
  • Any chimeric protein disclosed herein can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
  • DNA or RNA constructs encoding the protein sequences may also be used.
  • the composition is in the form of a capsule (see, e.g, U.S. Patent No. 5,698,155).
  • suitable pharmaceutical excipients are described in Remington’s Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds, 19th ed. 1995), incorporated herein by reference.
  • compositions comprising the chimeric protein can also include a solubilizing agent.
  • agents can be delivered with a suitable vehicle or delivery device as known in the art.
  • Compositions for administration can optionally include a local anesthetic such as, for example, lignocaine to lessen pain at the site of the injection.
  • compositions comprising the chimeric protein of the present disclosure may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing therapeutic agents into association with a carrier, which constitutes one or more accessory ingredients. Typically, the pharmaceutical compositions are prepared by uniformly and intimately bringing therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation (e.g, wet, or dry granulation, powder blends, etc, followed by tableting using conventional methods known in the art)
  • a carrier which constitutes one or more accessory ingredients.
  • the pharmaceutical compositions are prepared by uniformly and intimately bringing therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation (e.g, wet, or dry granulation, powder blends, etc, followed by tableting using conventional methods known in the art)
  • any chimeric protein disclosed herein is formulated in accordance with routine procedures as a pharmaceutical composition adapted for a mode of administration disclosed herein. Administration, Dosing, and Treatment Regimens
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the chimeric protein is administered by infusion wherein a post-dosing infusion related reaction (IRR) monitored during and immediately after the administration a dose; and (ii) slowing the rate of infusion if an IRR is observed during the dose and/or
  • the rate of infusion is decreased to about 90%, or about 80%, or about 75%, or about 70%, or about 60%, or about 50%, or about 40%, or about 33%, or about 30%, or about 25%, or about 20%, or less of the starting infusion rate.
  • the IRR is selected from headache, nausea, chills, pruritus, urticaria, fever, rigors, diaphoresis, dizziness, flush, bronchospasms, chest, and back pain.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level and/or activity of one or more of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 have been measured after at least 15 minutes after administering the first dose; and
  • the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2- fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20- fold greater), and/or the post-dosing level and/or activity of CCL22 is at least about 2-fold greater than a predose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of IL-10 is equal or less than about 1- fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a pre-dose amount or post-first dose amount
  • the second dose comprises substantially the same dosage as the first dose if: the postdosing level and/or activity of IL-12 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 6-fold greater, at least about 7-fold greater, at least about 8-fold greater, at least about 9-fold greater, at least about 10-fold greater, at least about 11 -fold greater, or at least about 12-fold greater), the post-dosing level and/or activity of CXCL-8 is at least about 3-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CXCL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of IL-10 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3- fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), the post-dosing level and/or activity of CCL2 is at least at least about 4-fold greater than a pre-dose amount or post-first dose amount (e.g.
  • the post-dosing level and/or activity of CCL20 is at least about 2-fold greater than a pre-dose amount or post- first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, at least about 4-fold greater, at least about 5-fold greater, at least about 10-fold greater, or at least about 20-fold greater), and/or the postdosing level and/or activity of CCL22 is at least about 2-fold greater than a pre-dose amount or post-first dose amount (e.g. at least about 2-fold greater, at least about 3-fold greater, or at least about 4-fold greater).
  • the second dose comprises an increased dosage compared to the first dose if the postdosing level and/or activity of IL-12 is equal or less than about 2-fold greater than a pre-dose amount or post- first dose amount, the post-dosing level and/or activity of CXCL-8 is equal or less than about 2-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CXCL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of IL-10 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, the post-dosing level and/or activity of CCL2 is equal or less than about 3-fold greater than a predose amount or post-first dose amount, the post-dosing level and/or activity of CCL20 is equal or less than about 1-fold greater than a pre-dose amount or post-first dose amount, and/
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a post-dosing level of CD47 receptor occupancy of CD4 T cells and/or CD40 receptor occupancy of B cells in a post-dose blood sample obtained from the subject have been measured after at least 15 minutes after administering the first dose; and (ii) administering
  • the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is measured less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level of CD47 occupancy of CD4 T cells and/or CD40 occupancy of B cells is less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%.
  • the post-dosing level of CD40 occupancy of B cells is measured using the following formula:
  • Receptor engagement %CR @ Predose wherein %CR @ predose is the percentage of target receptor-expressing lymphocytes in a pre-dose blood sample obtained from the subject; %CR @ postdose is the percentage of target receptor-expressing lymphocytes in the post-dose blood sample; and %CRI @ postdose is the percentage of the chimeric proteinbound CD40 + B cells in the post-dose blood sample, wherein: the presence, absence, or level of CD40 + B cells has been determined in the pre-dose blood sample, the presence, absence, or level of CD40 + B cells has been determined in the post-dose blood sample, and the presence, absence, or level of the chimeric protein-bound CD40 + B cells has been determined in the post-dose blood sample.
  • the post-dosing level of CD47 occupancy of CD4 T cells is measured using the following formula:
  • Receptor occupancy [%ARC(subj) — %ARC(iso)]/[%ARC(spike) — %ARC(ISO)] wherein %ARC(subj) is the percentage of chimeric protein-bound target receptor-expressing CD4+ T lymphocytes blood sample obtained from the subject; %ARC(iso) is the percentage of chimeric protein-bound target receptor-expressing CD4+ T lymphocytes blood sample obtained from the subject, stained with only drug detecting antibody; and %ARC(spike) is the percentage of chimeric protein-bound target receptorexpressing CD4+T lymphocytes blood sample obtained from the subject with a saturating amount of chimeric protein added at processing wherein: the presence, absence, or level of CD40 + B cells has been determined in the pre-dose blood sample, the presence, absence, or level of CD40 + B cells has been determined in the post-dose blood sample, and the presence, absence, or level of the chimeric protein-bound CD40 + B cells has been determined in the post-dose blood sample.
  • the present disclosure is based, in part, on the discoveries that (1) the target engagement of CD47 on CD4 T cells and CD40 on B cells approaches 100% by the 3 mg/kg dose level of the SIRPa-Fc-CD40L chimeric protein; (2) the margination CD40+ B cells from peripheral blood following the administration of the SIRPo- Fc-CD40L chimeric protein reaches maximum at the dosages > 3 mg/kg, and (3) the induction of IL-12, CXCL-8, CXCL-10, IL-10, CCL2, CCL20, and CCL22 following the administration of the SIRPa-Fc-CD40L chimeric protein approached a plateau at the dosages >3 mg/kg.
  • IRR infusion related reaction
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose at a dosage of at least about 0.3 mg/kg of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a background level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells has been measured in a pre-dose blood sample obtained from the subject before the administration of the first dose, wherein a post-dosing level
  • the post-dosing level and/or activity is measured more than about 12, or more than about 16, or more than about 18, or more than about 24, or more than about 28, or more than about 32, or more than about 40, or more than about 48 hours post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is lower compared to the background level and/or activity by at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% or more.
  • the second dose comprises an increased dosage compared to the first dose if the post-dosing level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is the chimeric protein not lower compared to the background level and/or activity by less than about 55%, or less than about 50%, or less than about 40%, or less than about 30%, or less than about 20%.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by contacting the sample with an agent that specifically binds to CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker.
  • the B-cell marker is selected from CD 19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD
  • the marker specific to CD40 expressing monocytes is selected from CD163, CD192, CD14, CD11 b, CCR2, CD16, CD141 , CD11c, HLA-DR, and CCR7
  • the CD4 T cell marker is selected from CD4, CD25, CD127, FoxP3, CCR4, Cith2, CCR6, CXCR5, CD39, CD45RA, CTLA-4, CD127, IL-2R, IL-4R, IL-9R, IL-15R, IL-21 R, and CD25.
  • the agent that specifically binds to CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level and/or activity of CD40+ B cells, CD40 expressing monocytes and/or CD4 T cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD47, CD40, CD4, a CD40+ B cell marker, a marker specific to CD40 expressing monocytes and/or a CD4 T cell marker.
  • the B-cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45, CD86, CD95, IgM, and IgD
  • the marker specific to CD40 expressing monocytes is selected from CD163, CD192, CD14, CD11 b, CCR2, CD16, CD141, CD11c, HLA-DR, and CCR7
  • the CD4 T cell marker is selected from CD4, CD25, CD127, FoxP3, CCR4, Cith2, CCR6, CXCR5, CD39, CD45RA, CTLA- 4, CD127, IL-2R, IL-4R, IL-9R, IL-15R, IL-21 R, and CD25.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer.
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid probe
  • the level and/or activity of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonu
  • the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg.
  • the present disclosure relates to a method for treating a cancer in a human subject, the method comprising: (i) administering to the human subject a first dose of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein a background amount and/or activity of M1 macrophages, M2 macrophages and/or granzyme B producing-T cells has been measured in a pre-dose biological sample obtained from the subject before the administration of the first dose, and wherein a postdose amount and/or activity of M1 macrophages
  • the post-dosing level and/or activity is measured more than about 12, or more than about 16, or more than about 18, or more than about 24, or more than about 28, or more than about 32, or more than about 40, or more than about 48 hours, or more post dosing.
  • the second dose comprises substantially the same dosage as the first dose if the post dosing amount and/or activity of the granzyme B producing-T cells is greater than the background amount and/or activity of the granzyme B producing-T cells by at least about 1 .25*, or at least about 1 .5x, or at least about 2x, or at least about 5x, or at least about 10x, or more.
  • the second dose comprises substantially the same dosage as the first dose if the post-dosing ratio of amount and/or activity of the M1 macrophages to M2 macrophages is greater than the pre-dose ratio of amount and/or activity of the M1 macrophages to M2 macrophages by at least about 1 .25*, or at least about 1 .5x, or at least about 2x, or at least about 5x, or at least about 10x, or more.
  • the second dose comprises an increased dosage compared to the first dose if the post dosing amount and/or activity of the granzyme B producing-T cells is not greater than the background amount and/or activity of the granzyme B producing-T cells by at least about 1.2x, or at least about 1 x. In embodiments, the second dose comprises an increased dosage compared to the first dose if the post-dosing ratio of amount and/or activity of the M1 macrophages to M2 macrophages is not greater than the pre-dose ratio of amount and/or activity of the M1 macrophages to M2 macrophages by at least about 1 .2x, or at least about 1 x.
  • the biological sample is selected from blood, plasma, serum, blood cells, lacrimal fluid, tears, bone marrow, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage, aspirate, scraping, bone marrow specimen, a biopsy specimen and a surgical specimen.
  • the biological sample is a biopsy sample or a surgical specimen, optionally wherein the biological sample is a tumor biopsy sample or a tumor surgical specimen.
  • the tumor biopsy sample or the tumor surgical specimen derived from a tumor selected ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the level of the cell is measured by RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof.
  • the level of the cell is measured by contacting the sample with an agent that specifically binds to a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells.
  • the marker specific to M1 macrophages is selected from CD80, CD86, CD64, CD16, CD32, and nitric oxide synthase (iNOS), the marker specific to M2 macrophages is selected from CD163, CD206, CD68, arginase 1 (Arg1) and DECTIN-1.
  • the marker specific to granzyme B producing-T cells is selected from granzyme B (GrzB), CD69 and integrin aE (CD103).
  • the agent that specifically binds to the a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells is an antibody or fragment thereof.
  • the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or fragment thereof.
  • the level of the cell is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding a marker specific to M1 macrophages, M2 macrophages and/or granzyme B producing-T cells.
  • the marker specific to M1 macrophages is selected from CD80, CD86, CD64, CD16, CD32, and nitric oxide synthase (iNOS)
  • the marker specific to M2 macrophages is selected from CD163, CD206, CD68, arginase 1 (Arg1) and DECTIN-1.
  • the marker specific to granzyme B producing-T cells is selected from granzyme B (GrzB), CD69 and integrin oE (CD103).
  • the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.
  • the level and/or activity of CD40+ B cells is measured by polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative PCR (qPCR), multiplex polymerase chain reaction, nested polymerase chain reaction, hot start polymerase chain reaction, long-range PCR, assembly polymerase chain reaction, asymmetric polymerase chain reaction, digital droplet PCR, a recombinase polymerase amplification (RPA), a loop-mediated amplification (LAMP), a helicase-dependent amplification (HDA), RNA or DNA gel electrophoresis or Southern or Northern blotting, a microarray-based assay, a hybridization technique, optionally selected from solution hybridization, capillary hybridization, hybridization to nucleic acid arrays, optionally macroarrays, microarrays or high-density oligonucleotide arrays (Gene Chips).
  • PCR polymerase chain reaction
  • RT-PCR reverse transcriptase
  • the chimeric protein is administered at the dosage of about 1 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 3 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 6 mg/kg. In embodiments, the chimeric protein is administered at the dosage of about 10 mg/kg.
  • the first domain is capable of binding a CD172a (SIRPa) ligand.
  • the first domain comprises substantially all of the extracellular domain of CD172a (SIRPa).
  • the first domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 57.
  • the second domain is capable of binding a CD40 receptor.
  • the second domain comprises substantially all of the extracellular domain of CD40L.
  • the second domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 58.
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from lgG4. In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human lgG4. In embodiments, the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the first domain comprises the amino acid sequence of SEQ ID NO: 57
  • the second domain comprises the amino acid sequence of SEQ ID NO: 58
  • the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7.
  • the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 and SEQ ID NO: 7.
  • the chimeric protein comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.2% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the chimeric protein comprises an amino acid sequence that is at least about 99.4% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.6% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.8% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the human subject suffers from or is suspected to suffer from an advanced solid tumor or a lymphoma.
  • the human subject suffers from or is suspected to suffer from a cancer is selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the human subject has failed one or more platinum-based therapies.
  • the human subject is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • a chimeric protein disclosed herein is presented as a sterile frozen solution at a concentration of about 20 mg/mL and a total volume of about 1 mL, optionally in a 10 mL glass vial.
  • a chimeric protein disclosed herein is administered by intravenous (IV) infusion following dilution with normal saline. Starting dose, dose escalation schema and dose schedules of certain embodiments are presented below.
  • the dose of the chimeric protein administered is at least 0.0001 mg/kg, e.g., between about 0.0001 mg/kg and about 10 mg/kg.
  • the dose of the chimeric protein administered is at least about 0.3 mg/kg, e.g., at least about 0.3 mg/kg, or about 1.0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg. In embodiments, the dose of the chimeric protein administered is at least about 1 mg/kg, e.g., at least about 1.0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the doses of the SIRPo-Fc-CD40L chimeric protein are not limited by anemia or another cytopenia effects and are therefore higher than doses are allowed compared to certain other therapeutics (e.g., anti-CD47 antibodies or SI RPalpha-Fc fusion protein). Further, in embodiments, a low dose priming is not needed.
  • the administration is intravenous. In embodiments, the administration is intratumoral. In embodiments, the administration is by injection. In embodiments, the administration is by infusion. In embodiments, the administration is performed by an intravenous infusion. In embodiments, the administration is performed by an intratumoral injection.
  • the human subject has failed one or more platinum-based therapies, and optionally is ineligible for a platinum therapy.
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy, and/or wherein the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • the initial dose is less than the dose for at least one of the subsequent administrations., e.g., each of the subsequent administrations.
  • the initial dose is the same as the dose for at least one of the subsequent administrations, e.g., each of the subsequent administrations.
  • the chimeric protein is administered at least about one time a month.
  • the chimeric protein is administered at least about two times a month.
  • the chimeric protein is administered at least about three times a month.
  • the chimeric protein is first administered once a week for three weeks and the chimeric protein is then administered about once every three weeks or once every four weeks. In embodiments, the chimeric protein is first administered once a week for three weeks and the chimeric protein is then administered about two times per month. For example, the chimeric protein is first administered once a week for three weeks and the chimeric protein is then administered about once every two weeks.
  • the chimeric protein is administered at least about four times a month.
  • the chimeric protein is administered about once a week.
  • the chimeric protein is administered once every week (once every seven days), in embodiments, the chimeric protein is administered once every two weeks.
  • the administration of the SIRPa-Fc-CD40L chimeric protein does not cause an anemia or another cytopenia in the patient. In embodiments, the administration of the does not cause lysis of RBCs. In embodiments, the administration of the SIRPa-Fc-CD40L chimeric protein is less likely to cause anemia or another cytopenia in than, e.g., an anti-CD47 Ab. In embodiments, the doses of the SIRPo-Fc-CD40L chimeric protein are not limited by anemia or another cytopenia effects and are therefore higher than doses are allowed compared to certain other therapeutics (e.g., anti-CD47 antibodies or SIRPalpha-Fc fusion protein). Further, in embodiments, a low dose priming is not needed.
  • SIRPo-Fc-CD40L chimeric protein offers is that despite targeting does not cause an anemia or another cytopenia in the patient. This is because although the CD47/SIRPO interaction plays a key role in the lysis of RBCs, as shown herein, the SIRPa-Fc-CD40L chimeric protein does not cause lysis of RBCs. Accordingly, the present methods are less likely to cause anemia or another cytopenia in than, e.g., an anti-CD47 Ab.
  • a chimeric protein may be administered intravenously by intravenous infusion or bolus injection into the bloodstream.
  • a chimeric protein may be administered intravenously by intravenous infusion for patients suffering from advanced ovarian, fallopian tube and primary peritoneal cancers.
  • a chimeric protein may be administered an intratumoral injection.
  • the therapeutic dose for intra-tumoral administration is equal or less than that of intravenous infusion. In embodiments, the therapeutic dose for intra-tumoral administration is equal to that of intravenous infusion. In embodiments, the therapeutic dose for intra-tumoral administration is less than that of intravenous infusion. In embodiments, the therapeutic dose for intra-tumoral administration for patients suffering from advanced or metastatic CSCC and HNSCC.
  • the present chimeric protein allows for a dual effect that provides less side effects than are seen in conventional immunotherapy (e.g., treatments with one or more of OPDIVO, KEYTRUDA, YERVOY, and TECENTRIQ).
  • the present chimeric proteins reduce or prevent commonly observed immune-related adverse events that affect various tissues and organs including the skin, the gastrointestinal tract, the kidneys, peripheral and central nervous system, liver, lymph nodes, eyes, pancreas, and the endocrine system, such as hypophysitis, colitis, hepatitis, pneumonitis, rash, and rheumatic disease.
  • Dosage forms suitable for intravenous administration include, for example, solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions (e.g., lyophilized composition), which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art.
  • any chimeric protein disclosed herein as well as the dosing schedule can depend on various parameters, including, but not limited to, the disease being treated, the subject’s general health, and the administering physician’s discretion.
  • the present disclosure relates to a method for treating a cancer in a human subject in need thereof, the method comprising a step of administering to the human subject an effective amount of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the step of administering comprises biphasic dosing.
  • a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a
  • the first phase, and the second phase each independently comprise a dosing frequency of from about twice a week to about once every two months.
  • the linker comprises at least one cysteine residue capable of forming a disulfide bond.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1 .5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about 3 mg/kg, or about 0.3 mg/kg to about 2.5 mg/kg, or about 0.3 mg/kg to about 2 mg/kg, or about 0.3 mg/kg to about 1 .5 mg/kg, or about 0.3 mg/kg to about 1 .0 mg/kg, or about 0.3 mg/kg to
  • the dosing frequency of the first phase, and the dosing frequency of the second phase are the same. In other embodiments, the dosing frequency of the first phase, and the dosing frequency of the second phase are different. In embodiments, the dosing frequency of the first phase is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing frequency of the first phase is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and , about every 6 weeks to about every 2 months.
  • the dosing frequency of the second phase is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing frequency of the second phase is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and , about every 6 weeks to about every 2 months.
  • the dosing frequency of the first phase is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks; and the frequency of the second phase is selected from about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks.
  • the first phase, and the second phase each independently last from about two days to about 12 months. In embodiments, the first phase lasts from about two weeks to about 2 months; and the second phase lasts from about 2 weeks to about 12 months. In embodiments, the first phase lasts from about two weeks to about 1 month; and the second phase lasts from about 2 weeks to about 12 months. In embodiments, the first phase lasts from about two weeks to about 1 month; and the second phase lasts from about 4 weeks to about 12 months. Additionally, or alternatively, in embodiments, the effective amount for the first phase, the second phase and the third phase each independently comprise about 0.01 mg/kg to about 10 mg/ml.
  • the effective amount for the first phase, the second phase and the third phase each independently selected from about 0.03 mg/kg, about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, and any range including and/or in between any two of the preceding values.
  • the effective amount for the first phase, the second phase and the third phase each independently selected from about 0.01 mg/kg to about O.1 mg/kg, about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, and about 1 mg/kg to about 10 mg/kg.
  • the effective amount for the first phase, the second phase and the third phase are same.
  • the effective amount for the first phase, the second phase and the third phase are different. In embodiments, the effective amount for the first phase is greater than the effective amount for the second phase. In embodiments, the effective amount for the first phase is from about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg; and the effective amount for the second phase is from about 0.01 mg/kg to about 0.1 mg/kg, about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg.
  • the chimeric proteins disclosed herein is the human CD172a (SIRPa)-Fc-CD40L chimeric protein.
  • the present disclosure relates to a method for treating a cancer in a human subject in need thereof the method comprising a step of administering to the human subject an effective amount of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPo)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), wherein the step of administration comprises a first cycle, a second cycle and a third cycle.
  • a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human
  • the linker comprises at least one cysteine residue capable of forming a disulfide bond.
  • the first cycle, the second cycle and the third cycle each independently comprise a dosing frequency of from about twice a week to about once every two months.
  • the dosing frequency of the first cycle, the dosing frequency of the second cycle and the dosing frequency of the third cycle are the same.
  • the dosing frequency of the first cycle, the dosing frequency of the second cycle and the dosing frequency of the third cycle are different.
  • the dosing frequency of the first cycle is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1 .5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about
  • the chimeric protein does not exhibit a bell-shaped dose response.
  • the dosing frequency of the first cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every
  • the dosing frequency of the second cycle is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing frequency of the second cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every every
  • the dosing frequency of the third cycle is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing frequency of the third cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and , about every 6 weeks to about every 2 months.
  • the dosing frequency of the first cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks; and the frequency of the second cycle is selected from about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks.
  • the first cycle, the second cycle and the third cycle each independently last from about two days to about 12 months. In embodiments, the first cycle lasts from about two weeks to about 2 months; and the second cycle lasts from about 2 weeks to about 12 months. In embodiments, the first cycle lasts from about two weeks to about 2 months; the second cycle lasts from about 2 weeks to about 12 months and the third cycle lasts from about 2 weeks to about 6 months.
  • the effective amount for the first cycle, the second cycle and the third cycle each independently comprise about 0.01 mg/kg to about 10 mg/ml. In embodiments, the effective amount for the first cycle, the second cycle and the third cycle each independently selected from about 0.03 mg/kg, about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, and any range including and/or in between any two of the preceding values.
  • the effective amount for the first cycle, the second cycle and the third cycle each independently selected from about 0.01 mg/kg to about O.1 mg/kg, about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, and about 1 mg/kg to about 10 mg/kg.
  • the effective amount for the first cycle, the second cycle and the third cycle are same. In other embodiments, the effective amount for the first cycle, the second cycle and the third cycle are different. In embodiments, the effective amount for the first cycle is greater than the effective amount for the second cycle. In other embodiments, the effective amount for the first cycle is lesser than the effective amount for the second cycle. In yet other embodiments, the effective amount for the first cycle and the effective amount for the second cycle are the same.
  • the effective amount for the first cycle is from about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg; and the effective amount for the second cycle is from about 0.01 mg/kg to about 0.1 mg/kg, about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg.
  • the chimeric proteins disclosed herein is the human CD172a (SIRPa)-Fc-CD40L chimeric protein.
  • the present disclosure relates to a method for treating a cancer in a human subject in need thereof the method comprising a step of administering to the human subject an effective amount of an effective amount of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)J, (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L) with a dosing regimen, wherein the dosing regimen comprises dosing with a frequency in the range of about every three days to about every 2 months
  • the linker comprises at least one cysteine residue capable of forming a disulfide bond.
  • the dosing regimen is selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing regimen is selected from about every week, about every 10 days, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing regimen is about every 2 weeks, about every 3 weeks, or about every 4 weeks.
  • the present disclosure relates to a method for treating a cancer in a human subject in need thereof the method comprising a step of administering to the human subject an effective amount of an effective amount of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L) with a dosing regimen selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to
  • the linker comprises at least one cysteine residue capable of forming a disulfide bond.
  • the dosing regimen is about every week to about every 2 weeks, about every 10 days to about every 3 weeks, or about every 2 weeks to about every 4 weeks.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1 .5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about 3 mg/kg, or about 0.3 mg/kg to about 2.5 mg/kg, or about 0.3 mg/kg to about 2 mg/kg, or about 0.3 mg/kg to about 1 .5 mg/kg, or about 0.3 mg/kg to about 1 .0 mg/kg, or about 0.3 mg/kg to about 0.5 mg/kg.
  • the chimeric protein does not exhibit a bell-shaped dose response.
  • the first domain is capable of binding a CD172a (SIRPa) ligand.
  • the first domain comprises substantially all of the extracellular domain of CD172a (SIRPa).
  • the second domain is capable of binding a CD40 receptor.
  • the second domain comprises substantially all of the extracellular domain of CD40L.
  • the linker comprises a hinge-CH2-CH3 Fc domain derived from lgG4, e.g., human I gG4.
  • the linker comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the first domain comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:
  • the first domain comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the first domain comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 57.
  • the second domain comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:
  • the second domain comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 58. 1 n some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 58.
  • the second domain comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 58.
  • the first domain comprises the amino acid sequence of SEQ ID NO: 57
  • the second domain comprises the amino acid sequence of SEQ ID NO: 58
  • the linker comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7. In embodiments, the chimeric protein further comprises the amino acid sequence of SEQ ID NO: 5 and SEQ ID NO: 7. In embodiments, the chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the chimeric protein comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 59 or SEQ ID NO: 61 . In embodiments, the chimeric protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61 . In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61 .
  • the chimeric protein comprises an amino acid sequence that is at least about 99.2% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.4% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.6% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.8% identical to SEQ ID NO: 59 or SEQ ID NO: 61 .
  • the chimeric protein comprises the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.
  • the human subject has received, been tolerant to, or is ineligible for standard therapy and/or the cancer has no approved therapy considered to be standard of care.
  • the present disclosure relates to a method for promoting the migration of lymphocytes from peripheral blood into secondary lymphoid organs e.g. the lymph nodes and spleen in a human subject in need thereof, the method comprising a step of administering to the human subject an effective amount of a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L).
  • the human subject is not receiving a concurrent chemotherapy, immunotherapy, biologic or hormonal therapy.
  • the present disclosure relates to a chimeric protein for use in the method of any of the embodiments disclosed herein.
  • the present disclosure relates to a chimeric protein comprising an amino acid sequence that is at least about 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61 . In embodiments, the chimeric protein comprises an amino acid sequence that is identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the dosing frequency of the first phase, and the dosing frequency of the second phase may be same or different.
  • the dosing frequency of the first phase and the dosing frequency of the second phase are each independently selected from about every three days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about 7 seven weeks, about every 8 weeks and about every 2 months.
  • the dosing frequency of the first phase is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and , about every 6 weeks to about every 2 months.
  • the first phase, and the second phase each independently last from about two days to about 12 months.
  • the first phase lasts from about two weeks to about 2 months; and the second phase lasts from about 2 weeks to about 12 months.
  • the first phase lasts from about two weeks to about 1 month; and the second phase lasts from about 2 weeks to about 12 months. In embodiments, the first phase lasts from about two weeks to about 1 month; and the second phase lasts from about 4 weeks to about 12 months.
  • the effective amount for the first phase, the second phase and the third phase may be same or different.
  • the effective amount for the first phase, the second phase and the third phase each independently comprise about 0.01 mg/kg to about 10 mg/ml.
  • the effective amount for the first phase is from about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg; and the effective amount for the second phase is from about 0.01 mg/kg to about 0.1 mg/kg, about 0.03 mg/kg to about 0.3 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.3 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 10 mg/kg.
  • the chimeric proteins disclosed herein is the human CD172a (SIRPa)-Fc-CD40L chimeric protein.
  • the human CD172a (SIRPo)-Fc-CD40L chimeric protein is capable of providing a sustained immunomodulatory effect.
  • the linker comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the linker comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3. In embodiments, the linker comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2, or SEQ ID NO: 3.
  • the linker comprises hinge-CH2-CH3 Fc domain derived from IgG. In embodiments, the linker comprises hinge-CH2-CH3 Fc domain derived from an IgG selected from lgG1 and lgG4. In embodiments, the linker comprises hinge-CH2-CH3 Fc domain derived from human I gG1 or human I gG4. In embodiments, the linker comprises hinge-CH2-CH3 Fc domain derived from lgG4. In embodiments, the hinge-CH2-CH3 Fc domain is derived from human I gG4.
  • the extracellular domain of human signal regulatory protein a comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 57.
  • the extracellular domain of human signal regulatory protein a comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57.
  • the extracellular domain of human signal regulatory protein a comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 57.
  • the extracellular domain of human signal regulatory protein a comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the extracellular domain of human signal regulatory protein a (CD172a (SIRPa)) comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 57. In embodiments, the extracellular domain of human signal regulatory protein a (CD172a (SIRPa)) comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 57.
  • the extracellular domain of human CD40 ligand comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 58.
  • the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58.
  • the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 58.
  • the extracellular domain of human CD40 ligand comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 58. In embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 58.
  • the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In embodiments, the human CD172a (SIRPa)-Fc-CD40L chimeric protein comprises an amino acid sequence that is identical to SEQ ID NO: 59 or SEQ ID NO: 61.
  • the present disclosure relates to a method for treating a cancer in a human subject comprising: (i) administering to the human subject a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge- CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L); and (ii) administering a second therapeutic agent.
  • a chimeric protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extra
  • the chimeric protein is administered at a dose between about 0.0001 mg/kg and about 10 mg/kg.
  • the dose of the chimeric protein administered is at least about 0.3 mg/kg, e.g., at least about 0.3 mg/kg, or about 1 .0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the dose of the chimeric protein administered is at least about 1 mg/kg, e.g., at least about 1.0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1 .5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about 3 mg/kg, or about 0.3 mg/kg to about 2.5 mg/kg, or about 0.3 mg/kg to about 2 mg/kg, or about 0.3 mg/kg to about 1 .5 mg/kg, or about 0.3 mg/kg to about 1 .0 mg/kg, or about 0.3 mg/kg to about 0.5 mg/kg.
  • the chimeric protein does not exhibit a bell-shaped dose response.
  • the administration of the chimeric protein causes a CD47 receptor occupancy (RO) on leukocytes that is at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% compared to the RO prior to administration of the chimeric protein, a second subject that is not administered the chimeric protein and/or an external control.
  • RO CD47 receptor occupancy
  • the administration of the chimeric protein causes a CD47 receptor occupancy (RO) on B cells that is at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% compared to the RO prior to administration of the chimeric protein, a second subject that is not administered the chimeric protein and/or an external control.
  • RO CD47 receptor occupancy
  • the administration of the chimeric protein causes an increase in the amount and/or activity of one or more of IL- 12, MCP-1, MIP-1 p, MIP-1a, and MDC % compared to the RO prior to administration of the chimeric protein, a second subject that is not administered the chimeric protein and/or an external control.
  • the present disclosure relates to a method for treating a cancer in a human subject comprising administering to a subject in need thereof: a chimeric protein of a general structure of N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge- CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L); wherein: the subject is undergoing or has undergone treatment with a second therapeutic agent.
  • a chimeric protein of a general structure of N terminus - (a) - (b) - (c) - C terminus wherein: (a) is a first domain
  • the chimeric protein is administered at a dose between about 0.0001 mg/kg and about 10 mg/kg.
  • the dose of the chimeric protein administered is at least about 0.3 mg/kg, e.g., at least about 0.3 mg/kg, or about 1 .0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the dose of the chimeric protein administered is at least about 1 mg/kg, e.g., at least about 1 .0 mg/kg, or about 2 mg/kg, or about 3, about 4 mg/kg, or about 6 mg/kg, or about 8 mg/kg, or about 10 mg/kg.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1.5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about 3 mg/kg, or about 0.3 mg/kg to about 2.5 mg/kg, or about 0.3 mg/kg to about 2 mg/kg, or about 0.3 mg/kg to about 1 .5 mg/kg, or about 0.3 mg/kg to about 1.0 mg/kg, or about 0.3 mg/kg to about 0.5 mg/kg.
  • the chimeric protein does not exhibit a bellshaped dose response.
  • the present disclosure relates to a method for treating a cancer in a human subject comprising administering to a subject in need thereof a second anticancer therapeutic agent, wherein the subject is undergoing or has undergone treatment with a chimeric protein of a general structure of N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a first domain comprising an extracellular domain of human Signal regulatory protein a (CD172a (SIRPa)), (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge- CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L).
  • a chimeric protein of a general structure of N terminus - (a) - (b) - (c) - C terminus wherein: (a) is a first
  • the chimeric protein is administered at a dose between about 0.0001 mg/kg and about 10 mg/kg.
  • the chimeric protein exhibits a linear dose response in the dose range of e.g., about 0.3 mg/kg to about 3 mg/kg, or about 0.5 mg/kg to about 3 mg/kg, or about 0.7 mg/kg to about 3 mg/kg, or about 1 mg/kg to about 3 mg/kg, or about 1.5 mg/kg to about 3 mg/kg, or about 2 mg/kg to about 3 mg/kg, or about 2.5 mg/kg to about 3 mg/kg, or about 0.3 mg/kg to about 2.5 mg/kg, or about 0.3 mg/kg to about 2 mg/kg, or about 0.3 mg/kg to about 1 .5 mg/kg, or about 0.3 mg/kg to about 1 .0 mg/kg, or about 0.3 mg/kg to about 0.5 mg/kg.
  • the chimeric protein does not exhibit a bell-shaped dose response.
  • the chimeric protein is administered before the second therapeutic agent. In embodiments, the second therapeutic agent is administered before the chimeric protein. In embodiments, the second therapeutic agent and the chimeric protein are administered substantially together.
  • the second therapeutic agent is selected from an antibody, and a chemotherapeutic agent.
  • the antibody is capable of antibody-dependent cellular cytotoxicity (ADCC).
  • the antibody is selected from cetuximab, rituximab, obinutuzumab, Hul4.18K322A, Hu3F8, dinituximab, and trastuzumab.
  • the antibody is capable of antibody-dependent cellular phagocytosis (ADCP).
  • the antibody is selected from cetuximab, daratumumab, rituximab, and trastuzumab.
  • the antibody is capable of binding a molecule selected from carcinoembryonic antigen (CEA), EGFR, HER-2, epithelial cell adhesion molecule (EpCAM), and human epithelial mucin-1 , CD20, CD30, CD38, CD40, and CD52.
  • CEA carcinoembryonic antigen
  • EpCAM epithelial cell adhesion molecule
  • human epithelial mucin-1 CD20, CD30, CD38, CD40, and CD52.
  • the antibody is capable of binding EGFR.
  • the antibody is selected from Mab A13, AMG595, cetuximab (Erbitux, C225), panitumumab (ABX-EGF, Vectibix), depatuxizumab (ABT 806), depatuxizumab, mafodotin, duligotuzumab (MEHD7945A, RG7597), Futuximab (Sym004), GC1118, imgatuzumab (GA201), matuzumab (EMD 72000), necitumumab (Portrazza), nimotuzumab (h-R3), anitumumab (Vectibix, ABX-EGF), zalutumumab, humMRI , and tomuzotuximab.
  • the antibody is cetuximab.
  • the chemotherapeutic agent is an anthracycline.
  • the anthacycline is selected from doxorubicin, daunorubicin, epirubicin and idarubicin, and pharmaceutically acceptable salts, acids, or derivatives thereof.
  • the chemotherapeutic agent is doxorubicin.
  • the cancer comprises an advanced solid tumor (local and/or metastatic) or a lymphoma.
  • the cancer is selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • the cancer comprises an advanced solid tumor (local and/or metastatic) or advanced lymphoma.
  • the examples herein are provided to illustrate advantages and benefits of the present technology and to further assist a person of ordinary skill in the art with preparing or using the chimeric proteins of the present technology.
  • the examples herein are also presented in order to more fully illustrate the preferred aspects of the present technology.
  • the examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims.
  • the examples can include or incorporate any of the variations, aspects or embodiments of the present technology described above.
  • the variations, aspects or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects, or embodiments of the present technology.
  • This first-in-human, phase 1 dose escalation study evaluated SL-172154 as monotherapy in patients (pts) with advanced platinum resistant ovarian, fallopian tube and primary peritoneal cancers (PROC).
  • SL-172154 was administered intravenously across 5 dose levels (0.1, 0.3, 1.0, 3.0, 10 mg/kg). Dose escalation followed a modified toxicity probability interval 2 design. See FIG. 1 B. Objectives included evaluation of safety, doselimiting toxicity (DLT), recommended phase 2 dose, pharmacokinetic and pharmacodynamic (PD) parameters, and antitumor activity per RECIST 1.1.
  • DLT doselimiting toxicity
  • PD pharmacokinetic and pharmacodynamic
  • FIG. 1C shows the details of the study population.
  • FIG. 1D shows the details of the tumor characteristics.
  • Illustrative Inclusion Criteria were: • Histologically confirmed unresectable, locally advanced or metastatic ovarian cancer, primary peritoneal cancer or fallopian tube cancer
  • FIG. 1 E tabulates all causality AEs observed in >3 subjects.
  • FIG. 1 F shows the drug-related AEs (any grade) observed in >10% subjects. The following was noted regarding the overall adverse event (AE) profile:
  • G3/4 drug-related AEs >1 subject: AST increased (G3) and lymphopenia (G4), all were fully resolved with no dose modifications. Treatment was delayed for one subject for G3 ALT increase. These events occurred at doses of 3.0 mg/kg or 10.0 mg/kg.
  • SAEs 7 events reported in 6 (22%) subjects: embolism (2), sepsis (2), large intestine infection, lower Gl hemorrhage and small intestinal obstruction. None were considered related to SL-172154.
  • IRR Infusion Related Reactions
  • IRRs were typically limited to Cycle 1 Day 1 (C1 D1), C1 D8. At 10.0 mg/kg IRRs were recurrent, occurring beyond C1 D1, C1 D8
  • Common symptoms of the IRR events variably included fever, chills, rigors, back pain, rash, hyper/ hypotension, tachycardia, nausea, and visual symptoms
  • treatment-emergent AEs >15%) regardless of grade (G) included infusion related reaction (IRR) (67%), fatigue (44%), nausea (33%), back pain (26%), constipation, diarrhea (both 22%), decreased appetite and pruritus (both 19%).
  • IRR infusion related reaction
  • G3/4 treatment-related AEs >1 patients were AST increased (G3) and lymphopenia (G4), each in 2 pts (7%); all were fully resolved with no dose modifications.
  • the frequency of IRR events increased with increasing dose, and slowing the rate of infusion was utilized for mitigation.
  • SL-172154 Cmax and AUC increased with dose with greater than proportional exposure noted at 3 and 10 mg/kg potentially due to target saturation.
  • ADA low-titer anti-drug antibody
  • FIG. 2C shows dose-normalized PK parameters at Cycle 1 Day 1 (C1 D1) (left panels), Cycle 1 Day 15 (C1 D1) (middle panels), and Cycle 2 Day 1 (C1 D1) (right panels).
  • Cmax/D (top panels) and AUCiast/D (bottom panels) are shown.
  • FIG. 2D shows dose-normalized Cmax, which is the maximum observed concentration.
  • FIG. 2E shows dose-normalized AUCiast, which is the area under the curve, time 0 to last concentration.
  • SL-172154 exhibited greater than dose proportional pharmacokinetics at or above 3 mg/kg.
  • FIG. 3A and FIG. 3B demonstrate that SL- 172154 engages with the CD40 located on the B cells.
  • B cells represent a large pool of circulating immune cells expressing elevated levels of CD40.
  • Fluorescence activated cell sorting (FACS) panels were designed to interrogate CD40 receptor occupancy.
  • FACS Fluorescence activated cell sorting
  • FIG. 3A shows dose-dependent egress of CD40+ B cells.
  • FIG. 4A and FIG. 4B demonstrate the binding of SL-172154 to CD47 + cells.
  • FIG. 4A shows percentage receptor occupancy of CD47 on CD4 T cell with maximal occupancy noted between 1 mg/Kg and 3 mg/Kg. Without wishing to be bound by theory, the reduction of receptor occupancy seen at 10 mg/Kg may be due to CD4 T cell egress.
  • FIG. 4B shows the CD47 receptor saturation on CD4 T cells. These results indicate, inter alia, a dose dependent increase in CD47 receptor saturation on CD4 T cells, approaching 100% by > 3.0 mg/kg dose. Egress of CD4 T cells from the circulation was observed as a secondary pharmacodynamic effect of CD40 agonism. Without wishing to be bound by theory, the observed egress of CD4 T cells from the circulation may contribute to the observed variability in CD47 receptor saturation.
  • CD4 T cells were also counted and compared pre- and post-dosing. As shown in FIG. 7A to FIG. 7C, a dose-dependent egress of CD4 T cells was observed. Without wishing to be bound by theory, the reduction of receptor occupancy seen at 10 mg/Kg may be due to CD4 T cell egress.
  • Example 5 Cytokine Responses Induced by the SIRPa-Fc-CD40L Chimeric Protein (SL-172154)
  • FIG. 6A shows that SL-172154 induced dose-dependent responses in IL-12 after the first infusion. Specifically, IL-12 change over C1 D1 predose showed a dose-dependent increase, approaching a plateau at >3 mg/kg.
  • FIG. 6B shows that the mean IL-12 concentrations over time. Cyclical increases in IL-12, a mediator of TH1 proinflammatory responses is observed in study subjects.
  • FIG. 6C shows that SL-172154 induced dosedependent responses in CXCL-8 which approached a plateau at >3 mg/kg. Specifically, CXCL-8 change over C1 D1 predose is shown.
  • FIG. 6A shows that SL-172154 induced dose-dependent responses in IL-12 after the first infusion. Specifically, IL-12 change over C1 D1 predose showed a dose-dependent increase, approaching a plateau at >3 mg/kg.
  • FIG. 6B shows that the mean IL-12 concentrations over time. Cyclical increases in IL-12, a mediator of TH1 proinflammatory
  • FIG. 6D shows that SL-172154 induced dose-dependent responses in CXCL- 8 after the first infusion. Specifically, CXCL-8 change over C1 D1 predose showed a dose-dependent increase, approaching a plateau at >3 mg/kg.
  • FIG. 6E shows that SL-172154 induced dose-dependent responses in CXCL-10 which approached a plateau at ⁇ 3 mg/kg. Specifically, CXCL-10 change over C1 D1 predose is shown.
  • FIG. 6F shows that SL-172154 induced dose-dependent responses in CXCL-8 after the first infusion. Specifically, CXCL-10 change over C1 D1 predose showed a dose-dependent increase, approaching a plateau at >3 mg/kg.
  • FIG. 6G shows that SL-172154 induced dose-dependent responses in IL-10 which approached a plateau at >3 mg/kg. Specifically, IL-10 change over C1 D1 predose is shown.
  • FIG. 6H shows that SL-172154 induced dose-dependent responses in IL-10 after the first infusion. Specifically, IL-10 change over C1 D1 predose showed a dose-dependent increase, approaching a plateau at >3 mg/kg.
  • FIG. 6I shows that SL-172154 induced dose-dependent responses in CCL2 which approached a plateau at >3 mg/kg. Specifically, CCL2 change over C1 D1 predose is shown.
  • FIG. 6J shows that SL-172154 induced dose-dependent responses in CCL20 which approached a plateau at >3 mg/kg.
  • FIG. 6K shows that SL-172154 induced dose-dependent responses in CCL22 which approached a plateau at >3 mg/kg.
  • CCL22 change over C1 D1 predose is shown.
  • lymphocytes following the treatment with SL-172154 were explored. Blood samples were obtained pre-dose, and 1 hour post-dose and 24 hour post-dose treated from patients with different doses and were subjected to lymphocyte counts. The changes in lymphocyte counts 1 hour post-dose, and 24 hour post-dose compared to the pre-dose sample was evaluated. As shown in FIG. 7A, the B cells rapidly marginated from the circulation post infusion in a dose-dependent manner. Maximal B cell margination was observed at 3 mg/kg and 10 mg/kg doses (FIG. 7A). Interestingly, unlike the lower doses, the patients treated with higher doses of SL-172154 showed reduced numbers of B cells returning to blood in the 24-hour blood samples (FIG. 7A). As shown in FIG.
  • Example 7 Correlation of the Pharmacological Activity of the SIRPa-Fc-CD40L Chimeric Protein (SL- 172154) with the Simulation in B cell Margination and IL-12 Stimulation
  • B cell margination was modeled in a PK/PD model. As shown in FIG. 8A, B cell margination showed a dose-dependent increase till about 3 mg/kg dose. Near maximal egress of B cells is reached at 3.0 mg/kg and did not change at 10.0 mg/kg (FIG. 8A), at the doses that show pharmacological activity. Given than doses of >3 mg/kg were efficacious, these results demonstrate, inter alia, a correlation between efficacy and the B cell margination.
  • IL-12 induction showed a dose-dependent increase till about 3 mg/kg dose.
  • IL-12 levels trended towards a plateau at >3.0 mg/kg (FIG. 8B).
  • doses of >3 mg/kg were efficacious, these results demonstrate, inter alia, a correlation between efficacy and the IL-12 induction.
  • Example 8 Induction of Polarization to M1 Macrophages and Infiltration of Cytotoxic T cells in the Tumor Nest by the SIRPa-Fc-CD40L Chimeric Protein (SL-172154).
  • SL-172154 was administered to an ovarian cancer patient.
  • a tumor biopsy sample was obtained from the patient prior to and after the administration of SL-172154.
  • the biopsy samples were analyzed for CD68, CD206, MHC II, CD3, CD8 and granzyme B-expressing cells.
  • CD68, CD206, MHC II, CD3, CD8 and granzyme B-expressing cells increased in tumor following the administration of SL-172154.
  • M1 and M2 macrophages were analyzed in tumor stroma and tumor nest. As shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne, en partie, des compositions et des procédés, y compris des protéines chimériques, qui trouvent une utilisation dans le traitement d'une maladie, telle que des immunothérapies pour le cancer.
PCT/US2024/015542 2023-02-13 2024-02-13 Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a Pending WO2024173352A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363484727P 2023-02-13 2023-02-13
US63/484,727 2023-02-13
US202363502039P 2023-05-12 2023-05-12
US63/502,039 2023-05-12

Publications (2)

Publication Number Publication Date
WO2024173352A2 true WO2024173352A2 (fr) 2024-08-22
WO2024173352A3 WO2024173352A3 (fr) 2024-10-24

Family

ID=92420638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/015542 Pending WO2024173352A2 (fr) 2023-02-13 2024-02-13 Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a

Country Status (1)

Country Link
WO (1) WO2024173352A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608751A1 (fr) * 2005-05-18 2006-11-23 Novartis Ag Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
JP2023541996A (ja) * 2020-09-17 2023-10-04 シャタック ラボ，インコーポレイテッド ＳＩＲＰ１αキメラタンパク質の臨床投与

Also Published As

Publication number Publication date
WO2024173352A3 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
CN110381983B (zh) 基于tigit和light的嵌合蛋白
CN108350055B (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP2023112192A (ja) サイトカイン融合タンパク質
CN112533944A (zh) 多特异性结合蛋白及其改进
US20250320268A1 (en) Clinical dosing of sirp1a chimeric protein
US20220185863A1 (en) Combination therapies
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
AU2019327493A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20200399344A1 (en) Nk cell-directed chimeric proteins
WO2023086929A1 (fr) Protéines chimériques à base de sirp1a et cd40l
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
WO2022187583A1 (fr) Polythérapies faisant appel à des protéines chimériques à base de tim-3
WO2022212845A2 (fr) Protéines chimériques à base de pd-1 et ox40l
JP2022531387A (ja) Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤
WO2024173352A2 (fr) Méthodes de traitement du cancer avec une protéine chimérique à base de sirp1a
WO2020205516A1 (fr) Dosage d'un anticorps bispécifique se liant à pd1 et ctla4
CN118510812A (zh) 基于sirp1a和cd40l的嵌合蛋白
CN116847866A (zh) 使用基于tigit和基于light的嵌合蛋白治疗癌症的方法
CN112888706A (zh) 包含基于tim-3的嵌合蛋白的组合疗法
WO2024123890A1 (fr) Méthodes d'utilisation de protéines chimériques à base de lumière
CN116670175A (zh) Sirp1a嵌合蛋白的临床给药

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24757527

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE